Curriculum Vitae

**David Carlton Henderson, M.D.**

**Boston Medical Center**

**Boston University School of Medicine**

**720 Harrison Avenue, Suite 914**

**Boston, Massachusetts 02118**

**T: 617.638.8141**

**F: 617.414.1996**

*David.Henderson@bmc.org*

**April 2020**

**Academic Training:**

1984 B.S., Tufts University, Medford, MA; Biology

1988 M.D., University of Massachusetts Medical School, Worcester, MA; Medicine

**Additional Training:**

 07/1988-06/1989 Intern in Medicine, St. Elizabeth’s Hospital, Brighton, MA

07/1989-06/1992 Residency, Psychiatry, Massachusetts General Hospital, Boston, MA

 07/1989-06/1992 Clinical Fellow, Psychiatry, Harvard Medical School, Boston, MA

 07/1991-06/1992 Research Fellow, MGH Schizophrenia Clinical and Research Program, Freedom Trail Clinic, Boston, MA, Mentor: Donald Goff, MD

 07/1991-06/1992 Chief Resident in Psychiatry, Psychiatry, Massachusetts General Hospital, Boston, MA

**Academic Appointments:**

 07/1992-03/1999 Instructor of Psychiatry, Harvard Medical School**,** Boston, MA

 03/1999-06/2005 Assistant Professor, Psychiatry, Harvard Medical School, Boston, MA

 06/2005-11/2015 Associate Professor of Psychiatry, Harvard Medical School, Boston, MA

 02/2014-11/2015 Associate Professor of Epidemiology, Harvard School of Public Health, Boston, MA

 11/2015-Present Professor and Chair of Psychiatry, Boston University School of Medicine, Boston, MA

 11/2015-Present Assistant Dean, Diversity and  Inclusion

 11/2015-Present Adjunct Professor of Epidemiology, Harvard T.H. Chan School of public Health

**Hospital Appointments or Other Employment:**

 07/1992-12/1995 Clinical Assistant, Psychiatry, Massachusetts General Hospital

 07/1992-12/2001 Attending Psychiatrist, Psychiatry, Massachusetts Institute of Technology

 12/1996-12/1999 Assistant in Psychiatry, Psychiatry, Massachusetts General Hospital

 12/1999-12/2003 Assistant Psychiatry, Psychiatry, Massachusetts General Hospital

 07/1992-11/2015 Attending Psychiatrist, Psychiatry, Freedom Trial Clinic, Erich Lindemann Mental Health Center

 07/2003-12/2010 Visiting Scientist, Health Science & Technology, Massachusetts Institute of Technology

 12/2003-12/2013 Associate Psychiatrist, Psychiatry, Massachusetts General Hospital

 12/2013-Present Psychiatrist, Psychiatry, Massachusetts General Hospital

 11/2015-Present Chief of Psychiatry, Boston Medical Center

**Licenses and Certification:**

 1992-Present Massachusetts Medical License

 1997-Present American Board of Psychiatry and Neurology: Certification in Psychiatry

# Honors:

|  |  |  |
| --- | --- | --- |
| Year | Name of Honor/Prize | Awarding Organization |
| 1984  | Student Affairs Community Award for Outstanding Contribution to Community Life | Tufts University |
| 1984 | McCune Smith Natural Science Award | Tufts University |
| 1992  | Ernest Y. Williams, M.D. Clinical Scholars of Distinction Award | National Medical Association (Psychiatry and Behavioral Health Section) |
| 1994 | Black Achievers Award of Greater Boston | Y.M.C.A |
| 1995 | Bulfinch Award for Excellence in Teaching | Massachusetts General Hospital, Psychiatry Residency Training Program |
| 1996 | Honorable Mention, Teacher of the Year Award | Massachusetts General Hospital, Psychiatry Residency Training Program |
| 1998 | Outstanding Teacher Award | Massachusetts General Hospital, Psychiatry Residency Training Program |
| 2004 | Outstanding Psychiatry Award for Clinical Psychiatry | Massachusetts Psychiatric Society |
| 2005 | Department of Mental Health Distinguished Service Award for Research | Commonwealth of Massachusetts Executive Office of Health and Human Services |
| 2007 | Dr. Solomon Carter Fuller Award | American Psychiatric Association |
| 2007 | Distinguished Fellow | American Psychiatric Association |
| 2007 | Psychopharmacology Supervisor Award | Massachusetts General Hospital/McLean Adult Psychiatry Residency Training Program |
| 2008 | 2008 Distinguished Alumnus Award | Brockton High School Alumni Association |
| 2008 | America’s Leading Doctors | Black Enterprise |
| 2010 | Psychopharmacology Supervisor Award | MGH/McLean Adult Psychiatry Residency Training Program |
| 2011 | Partners in Excellence Award | Partners Healthcare, Inc. |
| 2012 | Partners in Excellence Award | Partners Healthcare, Inc. |
| 2012 | Psychopharmacology Supervisor Award | MGH/McLean Adult Psychiatry Residency Training Program |
| 2013 | Excellence in Research Mentoring | MGH Department of Psychiatry |
| 2014 | Exemplary Psychiatrist Award | National Alliance on Mental Illness |
| 2019 | Presidential Commendation for global mental health | American Psychiatric Association |
| 2019 | Alexander Gralnick, M.D. Award for Research in Schizophrenia | American Psychiatric Association |

[**Other Professional Positions**](http://cv.hms.harvard.edu/index.php?page=other)**:**

|  |  |  |
| --- | --- | --- |
| Year(s) | Position Title | Institution |
| 1992- 2002;2017-Present | Board of Directors | De Novo (formerly Community Legal Services and Counseling Center, INC) |
| 1995-2000 | Consultant | Harvard Program in Refugee Trauma, Harvard School of Public Health |
| 1995-1997 | Research Associate | Multicultural Mental Health Research Center, INC. |
| 1996-1998 | Consultant | National Basketball Association, National Basketball Players’ Association Professional Network |
| 1997-2002  | Senior Research Associate | Multicultural Mental Health Research Center |
| 2000- 2002 | Consultant | University of New South Wales, United Nations-Dili, East Timor  |
| 2000-2012 | Consultant and Treating Clinician | National Football League Players Association and the National Football League Management |
| 2001 | Consultant (including on-site in New York City after 9/11 attack) | Health Resources and Services Administration, Bureau of Primary Care and Bellevue Hospital leadership |
| 2003-2017 | Advisory Board | Community Legal Services and Counseling Center, INC. |
| 2004 | Consultant | Iraq Mental Health Redevelopment (sponsored by Fogarty International Center & US Department of State) |
| 2005 | Consultant (including on-site in New Orleans after Hurricane Katrina Disaster) | American Red Cross (National Office), Washington D.C., US |
| 2009 | Lead Technical Consultant | Ministry of Health and Social Welfare, Republic of Liberia  |
| 2010 | Consultant (including on-site in Haiti after earthquake) | Partners in Health |
| 2011-2014 | Technical Consultant  | Ethiopia Mental Health Policy, Republic of Ethiopia Ministry of Health |
| 2014 | Consultant | World Bank, Washington, DC |

[**Major Administrative Leadership Positions**](http://cv.hms.harvard.edu/index.php?page=admin)

Local:

|  |  |  |
| --- | --- | --- |
| 1992-2015 | Director, Clozapine Program | Freedom Trail Clinic, Erich Lindemann Mental Health Center |
| 1995-1999 | Training CoordinatorPGY 4/PGY 5 Psychiatry Fellowship | Massachusetts Institute of Technology, Harvard Medical School |
| 1997-2012 | Associate Director, Schizophrenia Clinical and Research Program | Massachusetts General Hospital |
| 1999-2012 | Director, Schizophrenia Diabetes and Weight Reduction Research Program | Massachusetts General Hospital |
| 2000-2010 | Medical Director, Harvard Program in Refugee Trauma | Massachusetts General Hospital and Harvard Medical School |
| 2000-2011 | Associate Medical Director | Freedom Trail Clinic, North Suffolk Mental Health |
| 2007-2009 | Associate Director, International Division in Psychiatry | Massachusetts General Hospital |
| 2009-2015 | Director, The Chester M. Pierce, M.D. Division of Global Psychiatry | Massachusetts General Hospital  |
| 2010-2015 | Director, Liberia Center of Excellence in Mental Health and Psychiatry | Massachusetts General Hospital/Harvard Medical School – University of Liberia/A.M. Dogliotti College of Medicine |
| 2012-2015 | Director/Organizer, Global Psychiatry Residency Training Track | MGH/McLean Adult Psychiatry Residency Training Program |
| 2012-2015 | Director, Schizophrenia Clinical and Research Program | Massachusetts General Hospital |
| 2012-2018 | Co-Director, MGH Global Psychiatric Postdoctoral Clinical Research Training Program- NIMH T32 | Massachusetts General Hospital |
| 2015-Present | Chief of Psychiatry | Boston Medical Center |
| 2015-Present | President | Boston University Psychiatric Association |

**Regional:**

|  |  |  |
| --- | --- | --- |
| 2012;2017 | Co-Organizer, Disaster Psychiatry Course | Massachusetts Psychiatric Society and American Red Cross |

Committee Service

|  |  |  |
| --- | --- | --- |
| Year(s) of Membership | Name of Committee | Institution/Organization |
| Dates of Role(s) | Title of Role(s) |

Local:

|  |  |  |
| --- | --- | --- |
| 1992-2000 | Training Committee | Massachusetts Institute of Technology |
| 1992-2000 | Minority Student Concerns Committee | Massachusetts Institute of Technology |

|  |  |  |
| --- | --- | --- |
| 1992-1993 | Residency Training Committee | Massachusetts General Hospital |
| 1992-1996 | Committee on Diversity in Psychiatry, Chair | Massachusetts General Hospital  |
| 1992-1995 | Utilization Review and Quality Assurance Committee | Freedom Trail Clinic, North Suffolk Mental Health |
| 1992-2015 | Departmental Research Committee, Psychiatry | Massachusetts General Hospital |
| 1992-1995 | Human Rights Committee | Erich Lindemann Mental Health Center |
| 1998-2010 | Committee on Diversity in Psychiatry(Chair: 1998-2002) | Massachusetts General Hospital  |
| 1996-2000 | Committee on Learning Disabilities | Massachusetts Institute of Technology |
| 1996-2000 | Committee on Academic Performance | Massachusetts Institute of Technology |
| 2009-2015 | Adult Psychiatry Residency Recruitment Selection Committee | Massachusetts General Hospital |
| 2009-2015 | Liberia Mental Health Work Group (Chair) | Massachusetts General Hospital |
| 2009-2015 | Diversity Committee | Massachusetts General Hospital |
| 2010-2015 | Center for Global Health Executive Committee | Massachusetts General Hospital |
| 2011-2015 | Executive Committee, MGH Psychiatry Diversity Center  | Massachusetts General Hospital |
| 2011-2015 | Public and Community Psychiatry Mental Health Disparities Committee  | Massachusetts General Hospital |
| 2012-2015 | Adult Clinical Research Steering Committee, Psychiatry | Massachusetts General Hospital |
| 2012-2015 | Psychiatry Steering Committee | Massachusetts General Hospital |
| 2012-2017 | Global Psychiatry T32 Selection Committee | Massachusetts General Hospital |
| 2015-Present | Executive Committee | Boston University School of Medicine |
| 2016-Present | Finance Committee | Boston University Medical Group |
| 2017- Present | Member | Boston University Medical Group Nominating Committee |
| 2017-Present | Board of Directors | Boston Accountable Care Organization |
| 2017-Present | Steering Committee | Boston Accountable Care Organization |

Regional:

|  |  |  |
| --- | --- | --- |
| Year(s) of Membership | Name of Committee | Institution/Organization |
| Dates of Role(s) | Title of Role(s) |

|  |  |  |
| --- | --- | --- |
| 1992-2000 | Multi-Cultural Advisory Committee | Massachusetts Department of Mental Health  |
| 1997-Present | Disaster Response Team | Massachusetts Psychiatric Society |
| 2012-2015 | Central Office Research Review Committee | Massachusetts Department of Mental Health |

National and International:

|  |  |  |
| --- | --- | --- |
| Year(s) of Membership | Name of Committee | Institution/Organization |
| Dates of Role(s) | Title of Role(s) |

|  |  |  |
| --- | --- | --- |
| 2011-Present | Trustees of Donations for Education | University of Liberia, Republic of Liberia |
| 2014-2015 | Council on Research | American Psychiatric Association |
| 2016-2017 | Council on International Psychiatry | American Psychiatric Association |
| 2016- Present | Global Data Safety Monitoring Board | National Institute of Mental Health |

**Professional Societies:**

|  |  |  |
| --- | --- | --- |
| Year(s) of Membership | Society Name |  |
| Dates of Role(s) | Title of Role(s) |

|  |  |  |
| --- | --- | --- |
| 1990-2013  | National Medical Association | MemberVice Chair, Psychiatry Section (2009-2011) |
| 1992-Present | American Psychiatric Association | MemberDistinguished Fellow (2006-) |
| 1992-1998 | American Medical Association | Member |
| 1992-1998 | Massachusetts Medical Society | Member |
| 1992-Present | Massachusetts Psychiatric Society | Member |
| 1999-2002 | Massachusetts Psychiatric Society | Executive Committee, Councilor |
| 1992-Present | Black Psychiatrists of America | Executive CommitteeMember at Large-East (1997-1999) |
| 1997-2005 | New England Medical Society | Member |
| 1999-2015 | Sigma Xi, The Scientific Research Society, Harvard-Radcliffe | Member |

Grant Review Activities:

|  |  |  |
| --- | --- | --- |
| Year(s) of Membership | Name of Committee | Institution/Organization |
| Dates of Role(s) | Title of Role(s) |

|  |  |  |
| --- | --- | --- |
| 2008-2012 | Research Committee | The Deutsche Forschungsgemeinschaft (German Research Foundation) and the German Federal Ministry of Education and Research Grant Reviewer  |
| 2009-2010 | Special Emphasis Panel: ITVC | NIH/NIMHApplication Reviewer |
| 2013-Present | National Institute of Mental Health Global Mental Health Data and Safety Monitoring Board | Member |
| 2017-Present | National Advisory Mental Health Council | National Institute of Mental Health |

#

# [Editorial Activities](http://cv.hms.harvard.edu/index.php?page=editorial): ad hoc

1992- Journal of Nervous and Mental Disease

1992- Journal of Orthopsychiatry

1994- [Journal of Clinical Psychopharmacology](http://en.wikipedia.org/wiki/Journal_of_Clinical_Psychopharmacology)

1994- Psychiatric Services

1994- Psychosomatic

1995- American Journal of Psychiatry

1995- Archives of General Psychiatry

1998- [Acta Psychiatrica Scandinavica](http://en.wikipedia.org/wiki/Acta_Psychiatrica_Scandinavica)

1998- Biological Psychiatry

1998- Psychopharmacology

1998- [Psychosomatic Medicine](http://en.wikipedia.org/wiki/Psychosomatic_Medicine_%28journal%29)

2000- British Journal of Psychiatry

2000- Current Psychiatry

2000- Journal of Psychiatric Research

2000- Neuropsychopharmacology

2000- [Schizophrenia Bulletin](http://en.wikipedia.org/wiki/Schizophrenia_Bulletin)

2000- Schizophrenia Research

2002- Advances in Therapy

2002- Canadian Journal of Psychiatry

2002- Diabetes

2002- Diabetes Care

2004- Brain Research

2004- CNS Drugs

2004- Journal of Neuroendocrinology

2004- Obesity

2005- [Behavioral and Brain Functions](http://en.wikipedia.org/wiki/Behavioral_and_Brain_Functions)

2005- BMC Psychiatry

2005- CNS Spectrum

2005- Lancet

2005 Neuropsychology

2005- Pharmacogenomics

2007 [Molecular Psychiatry](http://en.wikipedia.org/wiki/Molecular_Psychiatry)

2008 Clinical Lipidology

2008- [World Psychiatry](http://en.wikipedia.org/wiki/World_Psychiatry_%28journal%29)

2010 European Child & Adolescent Psychiatry

2010- [European Psychiatry](http://en.wikipedia.org/wiki/European_Psychiatry)

|  |
| --- |
| Journals for which you serve as a reviewer |

Other Editorial Roles:

|  |  |  |
| --- | --- | --- |
| Year(s) | Role | Journal Name |

|  |  |  |
| --- | --- | --- |
| 2008- | Editor-in-Chief, U.S. | *International Journal of Culture and Mental Health* |
| 2009- | Editorial Board | *Clinical Schizophrenia & Related Psychosis* |
| 2011- | Editorial Board | *Current Psychiatry* |
| 2018-  | Editorial Board | *JAMA Psychiatry* |

**Other Support:**

Current Funding:

|  |  |
| --- | --- |
| 05/19/2017 – 05/19/2020 | A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients with Cognitive Impairment Associated with Schizophrenia Treated with Antipsychotics |
|  | Roche TCRC, Inc. |
| PI  | $171,342 |
| This study will investigate the efficacy of 24 weeks of basmisanil treatment on cognitive function as measured by the MATRICS consensus cognitive battery (MCCB) neurocognitive composite score, in stable patients with cognitive impairment associated with schizophrenia (CIAS) treated with antipsychotics. |

|  |  |
| --- | --- |
| 07/01/2014 – 06/30/2024 | Psychiatric Residency and Psychology Intern Training Program |
|  | Massachusetts Department of Mental Health |
| PI  | $747,783 |
| To educate behavioral health professionals to provide excellent, culturally and linguistically competent service to those who receive care in the public sector. |

|  |  |
| --- | --- |
| 07/01/2014 – 06/30/2024 | Health and Education Awareness for Africans in Lowell (HEAAL) |
|  | Theodore Edson Parker Foundation |
| PI  | $10,000 |
| This project seeks to increase the capacity of Christ Jubilee International Ministries - a nondenominational Christian church with a predominantly African immigrant congregation in Lowell, MA - to address the physical and mental health needs of its congregation by identifying areas of focus through a needs assessment; implementing activities that promote health and mental wellbeing; and equipping church leaders and community members with the skills to act as resources for screening and referral for the community. |

|  |  |
| --- | --- |
| 07/01/2018 – 06/30/2023 | **Boston University Medical Campus-Massachusetts General Hospital Global Psychiatric Clinical Research Training Program**  |
|  | Under the Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32- PA 16-152)  |
| Dual-PI, Administrative PI | $499,860 |
| The proposed postdoctoral fellowship is a three-year clinical research training program that combines rigorous didactic instruction, clinical research methods training and immersive, mentored clinical research experiences in global settings to develop independent clinical scientists who can address the most pressing global mental health challenges. Fellows will complete a mentored research project at an international training site in Barbados, Ethiopia, Peru, South Africa or Uganda.  |

|  |  |
| --- | --- |
| 07/01/2018 – 06/30/2023 | **Development and validation of an electronic health record prediction tool for first episode psychosis** |
|  | for consideration under RO1 Parent-PA 16-160 |
| Site PI | $499,860 |
| The proposed study will develop and validate an early detection model for first-episode psychosis based on electronic health record data.  |

Past Funding:

|  |  |
| --- | --- |
| 7/1/2012-6/30/2018 | The MGH Global Psychiatric Clinical Research Training Program  |
| NIH/NIMH 1T32MH093310-01A1 (Henderson, Fricchione, PI) |
|  | PI  | $1,386,377  |
|  | The postdoctoral fellowship is a three-year training program that combines rigorous didactic instruction, clinical research methods training, practice in working effectively with disadvantaged communities, and immersive, mentored clinical research experiences in global settings. |

|  |  |
| --- | --- |
| 03/01/16 – 03/31/18 | Randomized, Multi-site, Parallel-group, Rater-blind Study Comparing Response with Aripiprazole Once Monthly and Standards of Care Oral Antipsychotics in Non-adherent Outpatients with Schizophrenia Identified using the Brief Adherence Rater Scale |
| Otsuka Pharmaceuticals/Montana State University subaward |
|  | PI  | $260,849 |
| This study will evaluate the response of non-compliant schizophrenia subjects in improved symptoms with this once monthly injection of Aripiprazole compared to traditional oral antipsychotics. |

|  |  |
| --- | --- |
| 1/1/1999-12/1/2002 | Sibutramine for olanzapine induced weight gain: a placebo controlled trial |
| Eli Lilly (Investigator initiated) |
|  | PI  | $125,400 ($18,810) |
| This 12-week double blind, randomized, placebo controlled study sought to determine if sibutramine, an approved weight loss agent, would lead to weight loss in patients taking olanzapine who had schizophrenia or schizoaffective disorder. |

|  |  |
| --- | --- |
| 1/1/1999-12/1/2002 | Insulin resistance and glucose effectiveness in atypical antipsychotic agents: Bergman’s Minimal Model frequent sampled glucose tolerance test. |
|  | Janssen Pharmaceutica (Investigator initiated) |
| PI  | $126,450 ($18,967) |
| This cross-sectional design was used to study the 2 drugs most clearly implicated (clozapine and olanzapine) and risperidone using a frequently sampled intravenous glucose tolerance test. |

|  |  |
| --- | --- |
| 9/1/2000-9/1/2004 | Insulin resistance and glucose effectiveness: comparing Quetiapine and Olanzapine and normal controls using Bergman’s Minimal Model frequent sampled glucose tolerance test |
|  | AstraZeneca (Investigator initiated) |
| PI  | $195,624 ($29,343) |
| This cross-sectional comparison study was designed to compare matched olanzapine- and quetiapine-treated schizophrenia patients and normal controls on measures of glucose metabolism. |

|  |  |
| --- | --- |
| 1/1/2000-12/1/2002 | Insulin resistance and glucose effectiveness: comparing ziprasidone and olanzapine with Bergman’s Minimal Model frequent sampled glucose tolerance test |
|  | Pfizer Pharmaceuticals (Investigator initiated) |
| PI  | 250,000 ($37,500) |
| This cross-sectional design was used to examine ziprasidone and olanzapine on measures of glucose metabolism in schizophrenia subjects |

|  |  |
| --- | --- |
| 7/1/2001-6/1/2003 | Insulin resistance and glucose effectiveness: comparing quetiapine and olanzapine with Bergman’s Minimal Model frequent sampled glucose test |
|  | NARSAD  |
| PI  | $60,000  |
| A cross-sectional comparison of quetiapine-treated and olanzapine-treated non-obese schizophrenia subjects with matched normal controls using a frequently sampled intravenous glucose tolerance test and nutritional assessment was conducted to evaluate insulin resistance and glucose metabolism. |

|  |  |
| --- | --- |
| 2/1/2003-1/1/2004 | Aripiprazole added to partial responders to clozapine in schizophrenia subjects |
| Bristol Meyers Squibb (Investigator initiated) |
|  | PI  | $60,000 ($9,000) |
| The major goal of the six-week open-label trial was to examine the effects of adjunctive aripiprazole in clozapine-treated subjects on weight, lipid and glucose metabolism, as well as positive and negative symptoms of schizophrenia. |

|  |  |
| --- | --- |
| 7/1/2003-2/28/2006 | A double-blind, placebo controlled trial of rosiglitazone for clozapine induced glucose metabolism impairment: Bergman’s Minimal Model. |
|  | 02T-271 Stanley Foundation  |
| PI | $244,849 ($36,734) |
| The major goal of this placebo controlled double blind study was to determine whether rosiglitazone, an insulin sensitizer, improved insulin resistance and glucose utilization in clozapine-treated subjects.  |

|  |  |
| --- | --- |
| 7/30/2004-6/30/2007 | Fellowship Grant |
| Sidney R. Baer Foundation Grant  |
|  | PI  | $77,398 ($5,417) |
| The funding supported enhanced clinical care for individuals with schizophrenia. |

|  |  |
| --- | --- |
| 1/1/2005- 11/30/2008  | Aripiprazole for clozapine associated medical morbidity |
| 5 RO1 MH072635-02 NIMH  |
|  | PI  | $596,772 ($149,239) |
| The major goals of this placebo controlled trial of aripiprazole were to examine aripiprazole’s effect on lipid metabolism, glucose metabolism, body composition and cardiovascular risk factors. |

|  |  |
| --- | --- |
| 3/30/2005-3/30/2007 | An open label trial of ziprasidone as an adjuvant for clozapine- or olanzapine-associated diabetes mellitus in chronic schizophrenia.  |
|  | Pfizer Global Pharmaceuticals (Investigator initiated) |
| PI  | $90,000 ($18,000) |
| This was a six-week, open label trial of the novel antipsychotic agent, ziprasidone, added to a stable dose of clozapine or olanzapine in 40 diabetes mellitus patients, patients with an impaired fasting glucose or insulin resistance with schizophrenia or schizoaffective disorder.  |

|  |  |
| --- | --- |
| 12/31/2005-12/31/2007 | A placebo-controlled trial of aripiprazole added to obese olanzapine-treated patients with schizophrenia |
|  | Eli Lilly and Company (Investigator initiated) |
| PI  | $107,964 ($16,194) |
| This study was a ten week, placebo-controlled, double-blind, cross-over, randomized trial of the novel antipsychotic agent, aripiprazole, added to 15 obese olanzapine-treated patients with schizophrenia. |

|  |  |
| --- | --- |
| 11/1/2007- 1/30/2010 | Ramelteon as an adjunct therapy in non-diabetic patients with schizophrenia |
| Takeda Pharmaceuticals, North America Inc. (Investigator initiated) |
|  | PI  | $202,219 ($50,555) |
| The major goal of this study was to conduct and examine results from a twelve week, placebo-controlled randomized trial of the novel compound, ramelteon, added to patients with schizophrenia for the reduction of weight and lipids. |

|  |  |
| --- | --- |
| 12/31/2008- 2/28/2010 | Metformin in the treatment of antipsychotic-induced weight gain in schizophrenia (METS) |
| NIMH Subcontract N01 MH90001 |
|  | PI  | $33,625 ($5,043) |
| This was a proposal to collect pilot data for a larger study that aimed to determine if Metformin is a useful adjunctive treatment for patients with chronic schizophrenia who are obese and are taking antipsychotic medications. |

|  |  |
| --- | --- |
| 1/1/2009-6/30/2009 | Republic of Liberia National Mental Health Policy |
| McCall MacBain Foundation  |
|  | PI  | $182,152 ($12,750) |
| Provide technical assistance to the Liberia Ministry of Health & Social Welfare in the development of the country’s National Mental Health Policy. |

|  |  |
| --- | --- |
| 12/28/2009- 12/27/2012 | Pravastatin and schizophrenia |
| Stanley Medical Research Institute 09T-1296 |
|  | PI  | $419,218 ($69,874) |
| A double–blind study of pravastatin as an adjunctive therapy in schizophrenia subjects to examine the effect of pravastatin on inflammatory markers, psychopathology, cognition and lipids. |

|  |  |
| --- | --- |
| 2012-2013 | Clinical and Biomarker Assessment of Efficacy of Cognitive Remediation in Patients with Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone  |
| Research Foundation for Mental Hygiene |  |
| PI | $226,054 |
| This is a randomized, rater-blinded study in which 140 patients with schizophrenia or schizoaffective disorder stabilized on lurasidone will complete 30 sessions of cognitive remediation (or an active cognitive control condition) over a four to six month period. |

|  |  |
| --- | --- |
| 7/12/2012-12/31/2013 | A multicenter, open-label study to assess hospitalization rates in adult subjects with schizophrenia treated prospectively for 6 months with aripiprazole IM depot compared with 6-month retrospective treatment with oral antipsychotics in a naturalistic community setting in the United States. |
|  | Otsuka Pharmaceuticals |
| PI  | $290,190 ($49,332) |
| The goal of this study is to compare inpatient psychiatric hospitalization rates retrospectively while on oral standard-of care (SOC) antipsychotic treatment(s) to the prospective phase after switching to aripiprazole IM depot. |

|  |  |
| --- | --- |
| 6/1/2009-5/30/2014 | Variation in the clinical management of patients with co-morbid schizophrenia and diabetes |
| NIH/NIMH MH081824-0182 (Luftey, PI) |
|  | Co-PI  | $54,221($14,465) |
| The major goal of this study is to determine the complex reasoning processes behind the disparities in medical care that is given to a schizophrenic population. |

|  |  |
| --- | --- |
| 8/7/2012-12/31/2014 | Clinical and biomarker assessment of efficacy of cognitive remediation in patients with schizophrenia or schizoaffective disorder stabilized on lurasidone |
|  | Research Foundation for Mental Hygiene (PI: Jeffrey A. Lieberman, M.D.) |
| Site PI  | $237,357 ($64,086) |
| The goal of this study is to optimize the likelihood of meaningful improvement in cognitive and psychosocial functioning in patients with schizophrenia or schizoaffective disorder in those stabilized on Lurasidone. |

|  |  |
| --- | --- |
| 12/1/2013-11/1/2015 | A Multicenter 40-week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Dose of EVP 6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy |
| EnVivo Pharmaceuticals |
| PI  | $89,724 |
| The goals are to assess the long-term safety of 1 and 2 mg doses of EVP-6124 tablets administered once daily for up to 52 weeks in subjects who received EVP-6124 in both the pivotal and extension studies and up to 26 weeks in subjects who were randomized from placebo to EVP-6124 upon entry into this extension study. |

|  |  |
| --- | --- |
| 12/1/2013-1/1/2015 | Health Education and Awareness for Africans in Lowell |
| Theodore Parker Foundation |
| PI  | $52,000 |
| This pilot project between MGH and Christ Jubilee International Ministries seeks to increase the capacity of the church to address the physical and mental health needs of its congregation—predominantly African immigrants—by (1) identifying priority areasof focus through a needs assessment; (2) implementing activities that promote health and mental wellbeing (a Wellness Fair); and (3) equipping church leaders and community members with the skills to act as resources for screening and referral to the community (through intensive training and education). |

|  |  |
| --- | --- |
| 1/1/2014-4/1/2015 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 (90 mg and 120 mg) as a Treatment in Subjects with Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses) |
| Reckitt Benckiser Pharmaceuticals Inc. |
| Role: Co-PI (Maurizio Fava, MD)  | $501,677 |
| The objective of this protocol is to assess the efficacy of RBP-7000 (90 mg and 120 mg) compared with placebo on the symptoms of schizophrenia over an 8-week treatment period using the change from baseline to end of treatment in the total Positive and Negative Syndrome Scale (PANSS) score, which is the sum of all 30 PANSS items. |

|  |  |
| --- | --- |
| 9/15/2012-12/31/2015 | Cross-sectional study to compare glucose and lipid metabolism in schizophrenia subjects treated with either iloperidone, olanzapine or risperidone |
|  | Novartis (Investigator initiated) |
| PI  | $199,686 ($48,296) |

|  |  |
| --- | --- |
| 4/1/2013-12/31/2015 | A Randomized, Double-blind, Placebo-controlled, Parallel, 12-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy |
| EnVivo Pharmaceuticals |
| PI  | $255,097 |
| The primary objectives of this study are to assess the safety and the efficacy of 2 doses of once daily EVP-6124 tablets (1 and 2 mg) as an adjunctive pro-cognitive treatment, versus placebo, when added to chronic, stable, atypical antipsychotic therapy in subjects with schizophrenia. |

|  |  |
| --- | --- |
| 7/1/2012 -06/30/16  | A placebo-controlled trial of folate with B12 in patients with schizophrenia with residual symptoms in Ethiopia  |
|  | Stanley Medical Research Institute  |  |
| PI | $296,943 ($38,732) |
| This study is a randomized sequential parallel design for double-blind phase fixed dose, 4-month trial of folate plus B12 as add-on therapy in 200 Ethiopian subjects with schizophrenia with stable residual positive or negative symptoms. |

**Current Unfunded Projects:**

|  |  |
| --- | --- |
| 2011- | Hopes and Dreams of Youth in Post-Conflict LiberiaPIThe purpose of this mentored-pilot research qualitative investigation is to gain an insider’s understanding of how Liberian children have experienced past events and current circumstances and what barriers they face in their daily lives. This study examines the relationship between the loss of a parent and children’s sense of identity and development of future goals in children ages 13-18. |

|  |  |
| --- | --- |
| 2011- | Traditional Medicine in LiberiaPIThe purpose of this mentored pilot-research qualitative investigation is to determine the understanding that Liberians have about mental illness, explore the treatment options available given the lack of formal psychiatric care and to explore the methods and techniques used by traditional healers who deliver this treatment. |
|  |
| 2011- | The Role of Substance Use and High Risk Behaviors of Public School Students in PIThe purpose of this mentored pilot-research qualitative investigation is to examine the present behaviors and beliefs of public school students regarding substance use and sexual behaviors in Monrovia, Liberia |

|  |  |
| --- | --- |
| 2011- | Assessing Mental Health and Psychosocial Status in Post-Conflict LiberiaPIThe purpose of this mentored pilot-research qualitative investigation is to develop a culturally-grounded measurement tool to assess psychological well-being and distress among adults in post-conflict Liberia. |
|  |  |

**Report of Local Teaching and Training**

**Teaching of Students in Courses:**

|  |  |  |
| --- | --- | --- |
| 1997 | Psychobiology of Trauma10 graduate students | Harvard School of Public Health1 lecture per year (8 hours a year) |
| 1997 | Rwanda: Evaluation of an Area of Mass Violence10 graduate students | Harvard Graduate School of Education1 lecture per year (6 hours a year) |
| 2003- | Culture and Mental Health WorkshopMulticultural InterclerkshipMedical students | University of Massachusetts Medical School 2 lectures/workshops (6 hours per year) |
| 2010, 2011 | Disaster mental healthSocial Capital and Mental Health CourseGraduate students | Tufts University, Fletcher School 2 lectures/workshops (6 hours per year) |
| 2010, 2011 | Disaster mental healthCommunity Health CourseUndergraduate students | Tufts University, School of Arts and Sciences1 lecture (3 hours per year) |
| 2011 | Global Mental Health Global Health Equity ElectiveMedical students | Boston University Medical School1 seminar (4 hours) |

**Formal Teaching of Residents, Clinical Fellows and Fellows (post-docs):**

|  |  |  |
| --- | --- | --- |
| 1990 | Psychogenic Polydipsia and Hyponatremia10 psychiatry residents, 10 attendings | Massachusetts General Hospital30 hours per year |
| 1990 | Nightmares10 psychiatry residents, 10 attendings | Massachusetts General Hospital30 hours per year |
| 1990 | The Paranormal Phenomena in Psychiatry10 psychiatry residents, 10 attendings | Massachusetts General Hospital30 hours per year |
| 1992-2015 | Psychopharmacology and Psychotic Disorders Seminar4 medical students | Massachusetts General Hospital5 times per year (15 hours per year) |
| 1992-2015 | Schizophrenia, Psychopharmacology, Antipsychotic Agents, Psychogenic Polydipsia Cultural Psychiatry and Case Conferences4 psychiatry residents, 10 staff, 2 medical students | Erich Lindeman Mental Health Center 6 times per year (15 hours per year) |
| 1992-2006 | Transition to Practice12-16 psychiatry residents | Massachusetts General Hospital1 lecture (2 hours per year) |
| 1992-2015 | EthnopsychopharmacologySocio-cultural Lecture SeriesPGY3 psychiatry residents | MGH/McLean Hospital2 lectures per year (3 hours) |
| 1993-2002 | Diversity Cross-Cultural Psychiatry SeminarDeveloper; 16 psychiatry residents | Massachusetts General Hospital25 hours per year |
| 1995- 2004 | Treatment of Psychosis12 psychiatry residents | Massachusetts General Hospital2 lectures per year (6 hours per year) |
| 1995-2003 | Cultural Issues in Primary Care12 psychiatry residents | Massachusetts General Hospital2 lectures per year (6 hours per year) |
| 1998-2005 | Diagnosis and Treatment of Psychosis12 psychiatry residents | Massachusetts General Hospital1 lecture per year (3 hours per year) |
| 2005-2012 | Medical MorbidityCommunity Psychiatry CoursePsychiatry residents | Harvard Longwood Psychiatry Residency Training Program/Mass. Mental Health Care2 lectures per year (5 hours per year) |
| 2007 | Medical Morbidity: Antipsychotic Agents and Metabolic Syndrome 35 Psychiatry Residents, 12 staff psychiatrists, 15 other professionals  | New York Medical College1 lecture and seminar (8 hours) |
| 2010-2015 | Management and Metabolic Effects of AntipsychoticsPGY-2 Psychiatry Residents | Massachusetts General Hospital 1 lecture per year  |
| 2011-2015 | Metabolic Syndromes and PsychopharmacologyPsychosomatic Fellows | Brigham and Women’s Hospital 1-2 lectures per year |
| 2011-2015 | Transition to Practice Seminar PGY4 psychiatry residents | University of Massachusetts Medical School1 lecture per year |
| 2011-2014 | Mental Health Issues in Refugee Medicine5 Fellows (Thomas S. Durant Refugee Medicine Fellowship) | Massachusetts General Hospital1 lecture per year (1 hour) |
| 2011-2013 | International Research Training Seminar 10 psychiatry residents | Massachusetts General Hospital20 hours per year (course co-leader)  |

# Clinical Supervisory and Training Responsibilities:

|  |  |  |
| --- | --- | --- |
| 1992-2000 | Premedical AdvisorMassachusetts Institute of Technology | 20 hours per year |
| 1992-1995 | Freshman Advisor Massachusetts Institute of Technology | 40 hours per year |
| 1992-2015 | Individual Psychopharmacology SupervisorMassachusetts General Hospital | 2-3 hours per week |
| 1992-2004 | Group Psychopharmacology Supervisor Massachusetts General Hospital | 1 hour per week |
| 1992-2015 | Individual Supervisor Clozapine Clinic, Freedom Trail Clinic | 2 hours per week |
| 1994-2015 | Psychiatry Training SupervisorMassachusetts General Hospital | 1-2 hours per month |
| 2006- | MentorNational Minority Mentors Network, American Psychiatric Association | 6-20 hours per year |

# [Formally Supervised Trainees](http://cv.hms.harvard.edu/index.php?page=trainees):

1992-2015 Supervise all residents in the MGH and MGH/McLean Psychiatry Residency Program on the Erich Lindemann/Community Psychiatry Rotation

|  |  |
| --- | --- |
| 1998-Present | Christina Borba, PhD, MPH, Assistant Professor (Psychiatry), Boston University Medical School  |
|  |  | Research focus: Socio-cultural aspects of schizophrenia in diverse populations and resource-constrained local and international settings |
|  | Accomplishments: 60 peer reviewed articles; mentored NCDEU Award; mentored NIH Loan Repayment Award; mentored K-01 Award  |
| 2002-2003 | Laura Kunkel, MD*,* Instructor in Psychiatry, Harvard Medical School |
|  | Research focus: Schizophrenia and obesity |
|  |  | Accomplishments: 2 peer reviewed articles; mentored NARSAD Award |
| 2003-2004 | Pearl Louie, MD, Instructor in Psychiatry, Harvard Medical School,  Accomplishments: 6 peer reviewed articles; mentored NCDEU Award |
| 2003-2007 | Anthony Weiss, MD, Chief medical officer of Upstate University Hospital Research focus: Schizophrenia and DM Treatment in Primary Care Medicine Accomplishments: 5 peer reviewed articles; NARSAD Award and K23 Award |
| 2004-2015 | Joshua Roffman, MD, Assistant Professor of Psychiatry, Harvard Medical School |
|  |  | Research focus: Genetics of folate metabolism, glucose, and lipid metabolism |
|  | Accomplishments: 3 peer-reviewed articles; NARSAD Award, K-award |
| 2004-2012 | Karleyton Evans, MD, Assistant Professor, Harvard Medical School |
|  |  | Research focus: Neuroimaging of panic disorder |
|  | Accomplishments: Mentored K-Award |
| 2005-2012 | Xiaoduo Fan, MD, MS*,* Associate Professor in Psychiatry, Univ. of Massachusetts Medical School |
|  | Research focus: Schizophrenia, glucose and lipid metabolism and effects on cognition and psychopathology |
|  |  | Accomplishments: 19 peer reviewed articles; mentored NARSAD Award, K23 Award, NCDEU Award |
| 2005-2007 | Mary Weber, Ph.D., Assistant Clinical Professor, University of Texas and Endowed Professor in Psychiatric Nursing, University of Colorado |
|  | Research focus: Glucose metabolism in African American and Hispanic women and antipsychotics. |
|  | Accomplishments: 1 peer reviewed article |
| 2006-2008 | Kiran Lulla, MD, Assistant Professor of Psychiatry, Tufts Medical School |
|  | Research focus: Metabolic effects of antipsychotic agents and cardiovascular risks |
|  |  | accomplishments:  |
| 2007-2008 | Bikash Sharma, MBBS, Resident in Psychiatry, Howard University |
|  | Research focus: Women, Schizophrenia and Cardiovascular Risk Models |
|  |  | Accomplishments: 7 peer reviewed articles; mentored NCDEU Award |
| 2007-2008- | Paolo Cassano, MD, PhD – Assistant Professor of Psychiatry HMS,  Hispanic attitudes towards psychotropic medicationsNicole Christian, M.D.- Resident in Psychiatry at MGH/McLean and now Child Psychiatry Fellow; Qualitative research project on traditional healers in Liberia; Current training on qualitative research and data analysis; SAMSHA/APA Minority Fellow |
| 2008-2015 | Ann Shinn, MD, Instructor in Psychiatry, Harvard Medical School K23 submitted- Schizophrenia and visual hallucinations |
| 2009-2011 | Mark Viron, MD- former Chief Resident Community and Global Psychiatry; Medical Director, Massachusetts Mental Health Center |
| 2009-2012 | Zhenghui Yi, MBBS, MS, Physician in Deputy Chief, Shanghai Mental Health Center Vice Director, General Psychiatry Wards, Shanghai Mental Health Center, China |
|  | Research focus: Side-effects of long-term clozapine treatment (metabolism syndromes) Antipsychotics and Metabolism Syndromes |
|  |  | Accomplishments: 3 peer reviewed articles |
| 2009-2012  | Jijun Wang, MD, PhD, Director, Department of EEG Source Imaging, Shanghai Mental Health Center, China |
|  | Research focus: Intervention techniques among patients at high risk for schizophrenia; The pathophysiological mechanisms of schizophrenia; Integrating multimodal neural imaging techniques; repetitive transcranial magnetic stimulation (rTMS) among schizophrenia patients |
|  |  | Accomplishments: 4 peer reviewed articles |
| 2010-2011 | Suzan Song, MD, MPH, Research Fellow, Stanford; doctoral candidate, VU University, Amsterdam |
|  | Research focus: Mental health in Liberia |
|  |  | Accomplishments: 1 peer-reviewed manuscript  |
| 2010-2013 | Oriana Vesga Lopez, MD, MGH/McLean Adult Psychiatry Resident PGY4 |
|  |  | Research focus: Psychosocial distress and wellbeing among Liberian adults |
|  | Accomplishments: Two travel-awards; 2 Manuscripts; Global Mental health fellowship 2013 |
| 2011-Present | Kavitha Kolappa, MD, MPH, MGH/McLean Adult Psychiatry Resident PGY1 |
|  |  | Accomplishments: UN Summit on Non-Communicable Diseases Conference; T32 Global Mental Health Fellowship |
| 2011-Present | Elizabeth Levey, MD, MGH/McLean Adult Psychiatry Resident PGY4- Chief Resident in Global Psychiatry; T32 Global Mental Health Fellowship |
|  |  | Research focus: Youth development in Liberia |
|  | Accomplishments: First-author on 5 peer-reviewed manuscript, 2 travel-award |
| 2011-2013 | Justin Chen, MD, MGH/McLean Adult Psychiatry Resident PGY4 |
| 2011-2014 | Nicole Quiterio, MD, Child Psychiatry Fellow, Stanford |
|  |  | Research focus: Substance use and high risk behaviors of public school students in Monrovia, Liberia |
| 2011-2014 | William Siu, MD, PhD, MGH/McLean Adult Psychiatry Resident PGY2 |
|  |  | Research focus: Examining inflammatory markers in schizophrenia patients in Ethiopia |
| 2011-Present | Kelly Irwin, MD, Instructor in Psychiatry, Harvard Medical School |
|  |  | Research project: The quality of treatment of breast cancer in the chronically mentally ill. |
| 2011-2013 | Joan Camprodon, MD, PhD, Assistant in Neuropsychiatry, Massachusetts General HospitalBrazil project examining cultural beliefs for seizure disorders |
| 2011-2015 | Maithri Ameresekere, MD, MSc, PGY2 MGH/McLean Adult Psychiatry Resident |
|  |  | Research project: Mental health issues in South Sudan; Traditional medicine in Liberia |
|  | Accomplishments: 2 peer-reviewed articles |
| 2011-2015 | Alex Tsai, MD, PhD, Assistant Professor of Psychiatry, Harvard Medical School |
|  |  | Research project: Depression and food stability in rural Uganda |
|  |  | Accomplishments: K23 Award |
| 2011-2014 | Hasani Baranyi, MD*,* MGH/McLean Adult Psychiatry Resident PGY3 |
|  |  | Research project: Understanding resiliency factors in African Americans; SAMSHA/APA Minority Fellow |
| 2011-2014 | Rachel Ross, MD, PhD, MGH/McLean Adult Psychiatry Resident PGY3 |
|  |  Mentorship focus: Mental health in Sierra Leone |
| 2011-Present | Gowri Agawam, BA, UMass. Medical Student III |
|  |  | Mentorship focus: Community-care, club-house model programs for chronically, severely mentally ill in global populations/South Africa |
| 2011-2013 | Neelam Thakurathi, MBBS, Research Fellow, Mass. General Hospital |
|  |  | Mentorship focus: Vitamin D and schizophrenia |
|  | Accomplishments: 1 peer-reviewed article |
| 2011-2015 | Louisa Sylvia, Ph.D., Assistant Professor of Psychology, Harvard Medical School |
|  |  | Research focus: Intervention for obesity and metabolic abnormalities in bipolar populations; Accomplishments: K23 Award |
| 2011-2014 | Melissa Matthews, MD, MGH/McLean Adult Psychiatry Resident PGY3 |
| 2011-2015 | Jennifer Gatchell, MD, PhD, MGH/McLean Adult Psychiatry Resident PGY3 |
| 2012-2015 | April Joy Damian, Harvard Medical Student III; Qualitative study of Yoga practices  |
| 2012-2013 | Joshua A. Williams, MD, Harvard Longwood Psychiatry-PGY1; Child soldiers in Liberia  |
| 2012-2015 | Hermioni Lokko, MD, MGH/McLean Adult Psychiatry Resident PGY1; Schizophrenia, race and metabolic syndrome |
| 2012-2015 | Keri Oxley, MD MPA, MGH/McLean Adult Psychiatry Resident PGY2 |
| 2012-2015 | Mardoche Sidor, MD, Child Psychiatry Fellow, Cambridge Health Alliance; SAMSHA/APA Minority Fellow |
| 2011- | Lazaro Zayas, MD/MGH Psychiatry Resident PG4 |
|  | Currently working on one manuscript together; Mentored on a research proposal conducted in Liberia; Current training on qualitative research and data analysis |
| 2011-2015 | Nicole Quiterio, MD/Harvard South Shore Resident |
|  | Currently a child psychiatry fellow at Stanford University; Submitted one manuscript together; Mentored on one research proposal conducted in Liberia; Current training on qualitative research and data analysis |
| 2011-2015 | Brittany Lange/Northeastern University Psychology Undergraduate Student |
|  | Completed two directed studies with a submitted manuscript |
| 2012-2013 | Willie Siu, MD PhD/MGH Psychiatry Resident PGY2 |
|  | Mentoring on one research trip to Ethiopia  |
| 2012-2015 | Nayla Khoury, MD MPH/Cambridge Health Alliance Psychiatry Resident PGY1 |
|  | Mentoring during a research elective conducting and analyzing qualitative research |
| 2012 | Jessica Talero/Northeastern University Psychology Undergraduate Student |
|  | Completed a directed study |
| 2012-2015 | Alaa Alhomaizi/Northeastern University Psychology Undergraduate Student |
|  | Organized Kuwait Mental Health Conference with MGH faculty; Completing a directed study and honors thesis on a qualitative study among Arab female college students and mental health; Graduate school, Columbia University PhD Program |
| 2012-2015 | Dalal Alhomaizi/Northeastern University Psychology Undergraduate Student |
|  | Organized Kuwait Mental Health Conference with MGH faculty; Completing a directed study and honors thesis on a qualitative study among people of Arab decent and their mental health seeking behavior. Graduate school, Columbia University PhD Program |
| 2012-2015 | Melissa Ulloa/Northeastern University Psychology Undergraduate Student |
|  | Completing a directed study on qualitative research and writing a manuscript on the training of Peruvian primary care physicians; Clozapine 20 year follow-up on medical morbidity |
| 2012-2015 | Brenda Vincenzi, M.D. Research Scientist. Co-authored 6 publications in schizophrenia and ethnopsychopharmacology |
| 2016-Present | Christy A. Denckla, Ph.D./ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Broad InstituteCo-mentored during postdoctoral fellowship in regards to her work in Kenya |
| 2017- Present | Emeke Agudile, MD MPH/ Department of Social and Behavioral Sciences at Harvard T.H. Chan School of Public Health  |
| 2019- | Seemi Qaiser SM2-Department of Global Health Harvard T.H. Chan School of Public Health |
| 2019- | Camille Dollinger SM2- Department of Epidemiology, Harvard T.H. Chan School of Public Health |
| 2019- |  Wei Chen Wang Department of Epidemiology, Harvard T.H. Chan School of Public Health |

**Formal Teaching of Peers (e.g., CME and other continuing education courses):**

Those presentations below sponsored by outside entities are so noted and the sponsor is identified:

|  |  |  |
| --- | --- | --- |
| 1994 | Train the Trainers: Methods of Promoting Cultural CompetenceDepartment of Mental Health and Framingham State College | Single presentationFramingham, MA |
| 1996-1998 | Antipsychotic Drugs: Common Clinical Problems, Clinical Case Discussions and QuestionsMassachusetts General Hospital | 6 hours per yearBoston, MA |
| 1998 | Impact of Culture on Early Intervention in SchizophreniaHarvard Medical School and Massachusetts Mental Hospital | 6 hoursBoston, MA |
| 1998 | Ethno Psychopharmacology: Compliance and Risk ManagementMulticultural Mental Health Research Center | 10 hoursBoston, MA |
| 1999 | Depression and Pharmacology ManagementHarvard Medical School | Single PresentationBoston, MA |
| 2000-2003 | Antipsychotic Drugs: Common Clinical Problems, Clinical Case Discussions and QuestionsMassachusetts General Hospital | 6 hours per yearBoston, MA |
| 2002-2003 | Schizophrenia, Psychotic Disorders & Metabolism: Managing Comorbid ConditionsJoslin Diabetes Center (Harvard Medical School Affiliate) | Lecture and PanelistPittsburg, PANew Orleans, LA |
| 2003 | Schizophrenia Treatments and Metabolic ConcernsJoslin Diabetes Center (Harvard Medical School Affiliate) | Two Presentations (4 hours)New Orleans, LA |
| 2003 | Addressing Issues in Schizophrenia, Gender, Race and EthnicityContinuing Medical Education CourseUniversity of California, Los Angeles | Single PresentationLos Angeles, CA |
| 2003 | Addressing Issues in Schizophrenia, Gender, Race and EthnicityContinuing Medical Education CourseUniversity of California, Los Angeles | Single PresentationBoston, MA |
| 2003 | Schizophrenia Treatments and Metabolic ConcernsCME Program: Schizophrenia, Diabetes & Metabolism: Prevention and InterventionJoslin Diabetes Center (Harvard Medical School Affiliate) | Lecture and PanelNew Orleans, LA |
| 2004 | Antipsychotic Drugs: Common Clinical Problems, Clinical Case Discussions & QuestionsSeminar Course: Psychiatry: A Comprehensive Update and Board PreparationHarvard Medical School – Dept. of Continuing Medical Education | Single PresentationBoston, MA |
| 2005 | Evaluating and Managing the Side Effects of Antipsychotic DrugsMass. General Hospital Psychiatry Academy Symposium  | Lecture and PanelAtlanta, GA |
| 2005 | Evaluating and Managing the Side Effects of Antipsychotic DrugsMass. General Hospital Psychiatry Academy Symposium (Chairperson) | Lecture and PanelDearborn, MI |
| 2005 | Evaluating and Managing the Side Effects of Antipsychotic DrugsMass. General Hospital Psychiatry Academy Symposium (Chairperson) | Lecture and PanelChicago, IL |
| 2005 | Evaluating and Managing the Side Effects of Antipsychotic DrugsMass. General Hospital Psychiatry Academia Symposium | Lecture and PanelNew York, NY |
| 2005 | Evaluating and Managing Side Effects of Antipsychotic DrugsMass. General Hospital Psychiatry Academia Symposium | Lecture and PanelPhiladelphia, PA |
| 2005 | Treatment Issues from the Psychiatrist’s Perspective: Treating Psychoses While Maintaining Medical HealthJoslin Diabetes Center (Harvard Medical School Affiliate) | Short Hills, NJ |
| 2005 | Evaluating and Managing Side Effects of Antipsychotic DrugsMass. General Hospital Psychiatry Academia Symposium | Lecture and PanelMinnetonka, MN |
| 2005 | Treatment Issues from the Psychiatrist’s Perspective: Treating Psychoses While Maintaining Medical HealthJoslin Diabetes Center (Harvard Medical School Affiliate) | Lecture and PanelNew York, NY |
| 2005 | Treatment Issues from the Psychiatrist’s Perspective: Treating Psychoses While Maintaining Medical HealthJoslin Diabetes Center (Harvard Medical School Affiliate) | Lecture and PanelPhiladelphia, PA |
| 2005 | Treatment Issues from the Psychiatrist’s Perspective: Treating Psychoses While Maintaining Medical HealthJoslin Diabetes Center (Harvard Medical School Affiliate) | Lecture and PanelDearborn, MI |
| 2006 | Metabolic Issues and Antipsychotic Treatments Optimizing Issues: Optimizing Antipsychotic EfficacyJoslin Diabetes Center (Harvard Medical School Affiliate) | Lecture and PanelCleveland, OH |
| 2006 | An Update on the Treatment of SchizophreniaMassachusetts General Hospital Psychiatry Academy Symposium (Chairperson) | Lecture and PanelChicago, IL |
| 2006 | An Update on the Treatment of SchizophreniaMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelDearborn, MI |
| 2006 | An Update on the Treatment of SchizophreniaMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelNew York, NY |
| 2006 | An Update on the Treatment of SchizophreniaMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelPhiladelphia, PA |
| 2006 | An Update on the Treatment of SchizophreniaMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelChantilly, VA |
| 2006 | An Update on the Treatment of SchizophreniaMassachusetts General Hospital Psychiatry Academy Symposium (Chairperson) | Lecture and PanelDallas, TX |
| 2007 | Cross-Cultural Considerations in Schizophrenia Spectrum DisordersMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelDetroit, MI |
| 2007 | Cross-Cultural Considerations in Schizophrenia Spectrum DisordersMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelSan Francisco, CA |
| 2007 | Cross-Cultural Considerations in Schizophrenia Spectrum DisordersMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelDallas, TX |
| 2007 | Cross-Cultural Considerations in Schizophrenia Spectrum DisordersMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelPhiladelphia, PA |
| 2007 | Cross-Cultural Considerations in Schizophrenia Spectrum DisordersMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelNew York, NY |
| 2007 | Cross-Cultural Considerations in Schizophrenia Spectrum DisordersMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelChicago, IL |
| 2007 | Cross-Cultural Considerations in Schizophrenia Spectrum DisordersMassachusetts General Hospital Psychiatry Academy Symposium | Lecture and PanelReston, VA (DC) |
| 2008 | Dynamic and Effective Psychiatric Care CourseMassachusetts General Hospital Psychiatry Academy | LectureNew York, NY |
| 2008 | Psychopharmacology SymposiumMassachusetts General Hospital Psychiatry Academy | LectureBoston, MA |
| 2009 | An Update on the Treatment of SchizophreniaPsychopharmacology SymposiumMassachusetts General Hospital Psychiatry Academy | LectureBoston, MA |
| 2010 | Identifying and Managing Antipsychotic-Induced Metabolic Effects Massachusetts General Hospital Psychiatry Academy | Lecture and PanelPhiladelphia, PA |
| 2010 | An Update on the Treatment of SchizophreniaPsychopharmacology SymposiumMassachusetts General Hospital Psychiatry Academy | LectureBoston, MA |
| 2010 | Clinical Simulation: Identifying and Managing Antipsychotic-Induced Metabolic Effects Massachusetts General Hospital Psychiatry Academy | Lecture and PanelBoston, MA (online) |
| 2012 | Culture and PsychiatryPsychiatry Board Exam Mastery Review CourseMassachusetts General Hospital Academy | Single Presentation (40-60 minutes) |
| 2012 | Managing Metabolic Side Effects of Psychotropic MedicationVirtual Grand Rounds: Spring 2012 SeriesMassachusetts General Hospital Psychiatric Academy | Single PresentationBoston, MA (online) |
| 2012 | Schizophrenia: Overview and Update on New TreatmentsPsychopharmacology 2012 SymposiumMassachusetts General Hospital Academy | Single PresentationBoston, MA |
| 2012 | Annual Psychopharmacology CourseSchizophrenia: Overview and Update on New TreatmentsManaging side effects of Antipsychotic AgentsMassachusetts General Hospital Academy | Two PresentationsBoston, MA |

**Local Invited Presentations:**

|  |  |
| --- | --- |
| 1993 | Atypical Antipsychotic Agents, Psychiatry Grand RoundsMassachusetts Institute of Technology, Cambridge, MA |
| 1994 | New advances in antipsychotic drugs, Psychiatry Grand RoundsMassachusetts General Hospital, Boston, MA |
| 1995 | Clinical Case Conference, PresenterMassachusetts General Hospital, Boston, MA |
| 1996 | Mental Health Crisis in Rwanda, LectureHarvard School of Public Health, Boston, MA |
| 1996 | Atypical Antipsychotic Agents, Psychiatry Grand RoundsMassachusetts Institute of Technology, Cambridge, MA |
| 1996 | Mental health in Cambodia, Psychiatry Grand RoundsMassachusetts Institute of Technology, Cambridge, MA |
| 1996 | Mental Health Crisis in Rwanda, Psychiatry Grand RoundsMassachusetts Institute of Technology, Cambridge, MA |
| 1998 | Atypical Antipsychotic Agents, Psychiatry Grand RoundsMassachusetts Institute of Technology, Cambridge, MA |
| 1998 | Diagnosis and Treatment of Depression, Psychiatry Grand RoundsMassachusetts Institute of Technology, Cambridge, MA |
| 1998 | Treatment of Psychotic Disorders, Psychiatry Grand RoundsMassachusetts Institute of Technology, Cambridge, MA |
| 2000 | Stress and Depression, LecturerMinority Women’s Health Forum, Massachusetts General Hospital, Boston, MA |
| 2000 | Cultural Factors in the Treatment of African Americans, LectureHarvard University, Cambridge, MA  |
| 2002 | Treatment of Schizophrenia: Atypical Neuroleptic Side Effects – Weight Gain and Diabetes, LectureHarvard Medical School, Boston, MA |
| 2004 | Mechanisms of Atypical Antipsychotics Agents’ Impairment of Glucose Metabolism, LectureThe Chester Pierce Research Society, Massachusetts General Hospital, Boston, MA |
| 2004 | Ethno psychopharmacology & African-American Mental Health in the 21st Century, LectureMassachusetts General Hospital, Boston, MA |
| 2010 | Program on Chronic PsychosisIdentifying and Managing Antipsychotic-Induced Metabolic EffectsMGH |
| 2010 | Psychosis, MGH Case ConferenceMassachusetts General Hospital, Boston, MA |
| 2010 | Global Mental Health Update, PresentationCenter for Global Health Executive Committee, Massachusetts General Hospital, Boston, MA |
| 2010 | Practicing Global Health Across Disciplines: Snapshots of Success, Presenter and PanelistMGH Center for Global Health Inaugural Symposium, Broadening the Response: the Role of Academic Medicine in Global Health, Boston, MA |
| 2010 | Haiti: Sustaining the Response, Presenter and PanelistMGH Center for Global Health Symposium, Massachusetts General Hospital, Boston, MA |
| 2010 | International Health, PanelistCenter for Public Leadership, Harvard Kennedy School, Cambridge, MA |
| 2010 | Models of Global Health Education, PanelistMGH Center for Global Health Seminar Series, Massachusetts General Hospital, Boston, MA |
| 2010 | Global Mental Health, PresenterCenter for Global Health Advisory Board, Massachusetts General Hospital, Boston, MA |
| 2010 | Global Mental Health: Current Needs, PresenterCenter for Global Health Advisory Board, Massachusetts General Hospital, Boston, MA |
| 2011 | Discussant, Psychosomatic Conference, Massachusetts General Hospital, Boston, MA |
| 2011 | Global Psychiatry: Liberia, Presenter Center for Global Health Executive Committee, Massachusetts General Hospital, Boston, MA |
| 2011 | Discussant, Psychosomatic Conference, Massachusetts General Hospital, Boston, MA |
| 2011 | Child Soldiers in Liberia, DiscussantPsychosomatic Case Conference, Massachusetts General Hospital, Boston, MA |
| 2011 | Role of Psychiatric Research in Policy Development in Africa, Lecture and Conference OrganizerCenter for Global Health Annual Symposium, *Global Mental Health and Africa*Massachusetts General Hospital, Mbarara, Uganda |
| 2011 | Liberia Mental Health, Update PresentationPsychiatry Steering Committee Meeting, Massachusetts General Hospital, Boston, MA |
| 2011 | Mental Health Needs in Liberia, Update/PresenterCenter for Global Health Advisory Board Meeting, Massachusetts General Hospital, Boston, MA |
| 2011 | Global Psychiatry, Update PresentationPsychiatry Steering Committee Meeting, Massachusetts General Hospital, Boston, MA |
| 2011 | Global Mental Health and Africa: Research and Training Needs, Presenter Center for Global Health Advisory Board Meeting, Massachusetts General Hospital, Boston, MA |
| 2011 | Budget Impact and Sustainability of Medical Care Management for Persons with Serious Mental Illnesses, Journal Club DiscussantMassachusetts General Hospital, Boston, MA |
| 2012 | Severely Mentally Ill and Co-morbid Chronic Medical Diseases, Psychiatry Grand RoundsMassachusetts General Hospital, Boston, MA |
| 2012 | Schizophrenia Program Update, PresentationPsychiatry Steering Committee Meeting, Massachusetts General Hospital, Boston, MA |
| 2012 | Building Global Mental Health Capacity, Lecture Psychiatry: A Dialogue Symposium, Dept. of Psychiatry, Mass. General Hospital/Partners HealthCare, Boston, MA |
| 2012 | Conducting Research in LMICs, LectureGlobal Psychiatry Seminar Series, Massachusetts General Hospital, Boston, MA |
| 2012 | Schizophrenia: the Next Ten Years10th Annual Schizophrenia Education Day, Massachusetts General Hospital, Boston, MA |
| 2012 | Trauma and Resiliency in Disasters and Post-Conflict Contexts, LecturePTSD/TBI Monthly Research Group, Massachusetts General Hospital, Boston, MA |
| 2012 | Managing Medication Side Effects in Schizophrenia, Virtual Grand RoundsMassachusetts General Hospital Psychiatry Academy, Boston, MA |
| 2013 | Research Training in Psychiatry, Presenter Center for Global Health Advisory Board Meeting, Massachusetts General Hospital, Boston, MA |

**Invited Lectures and Conference Presentations**

### Regional:

|  |  |
| --- | --- |
| 1993 | Antipsychotic Drugs-Update, LectureBournewood Hospital, Chestnut Hill, MA |
| 1993 | Understanding Nightmares, Psychiatry Grand RoundsDimock Street Health Center, Boston, MA |
| 1993 | Racism in Psychiatry, Psychiatry Grand RoundsDimock Street Health Center, Boston, MA |
| 1994 | Clozapine, Psychiatry Grand RoundsCape Cod Hospital, Hyannis, MA |
| 1994 | Treatment of Schizophrenia and Antipsychotic Drugs, Psychiatry Grand RoundsMaine Veterans Administration, Augustus, ME |
| 1994 | Understanding Antipsychotic Agents, Psychiatry Grand RoundsSouth Portland Mental Health Center, South Portland, ME |
| 1994 | Antipsychotic agents for Mood Disorders, Psychiatry Grand RoundsArbor Hospital, Boston, MA |
| 1994 | Treatment of Schizophrenia, Psychiatry Grand RoundsSouth Shore Mental Health Center, Quincy, MA |
| 1995 | Update on Antipsychotic Medications, Psychiatry Grand RoundsDepartment of Mental Health, Plymouth, MA |
| 1995 | Psychiatry, Race, and Ethnopsychopharmacology, Grand RoundsNew England Home for Little Wanderers, Boston, MA |
| 1996 | Atypical Antipsychotic Agents and Schizophrenia, Grand RoundsMedfield State, Hospital, Medfield, MA |
| 1996 | Doing Clinical Research in Psychiatry, Psychiatry Grand RoundsDr. Solomon Carter Fuller Mental Health Center, Boston, MA |
| 1997 | Update on Antipsychotic Drugs, Psychiatry Grand RoundsBournewood Hospital, Chestnut Hill, MA |
| 1997 | The Use of Antipsychotic Drugs in Brain Injury Patients, Psychiatry Grand RoundsNew England Rehabilitation Hospital, Woburn, MA |
| 1997 | Understanding New Antipsychotic Agents, Psychiatry Grand RoundsSt. Joseph’s Hospital, Providence, RI |
| 1997 | Working With Dental Patients with Mental Illness, LectureMass. Dental Hygienist Conference, Boston, MA |
| 1998 | Ethno psychopharmacology, Psychiatry Grand RoundsDr. Solomon Carter Fuller Mental Health Center, Boston, MA |
| 1998 | Ethno psychopharmacology, Psychiatric Grand RoundsJudge Baker-Children’s Hospital, Boston, MA |
| 1998 | The Positive and Negative Symptom of Change, Psychiatry Grand RoundsDr. Solomon Carter Fuller Mental Health Center, Boston, MA |
| 1999 | The Role of Glutamate and Atypical Antipsychotic Agents, Grand RoundsTufts Medical School, Boston, MA |
| 1999 | Ethno psychopharmacology, Grand RoundsWorcester State Hospital, Worcester, MA |
| 1999 | Case Conference PresentationSolomon Carter Fuller Mental Health Center, Boston, MA |
| 1999 | Case Conference PresentationMcLean Hospital, Belmont, MA |
| 2000 | Schizophrenia and Glucose Metabolism Impairment, Psychopharmacology Grand RoundsMcLean Hospital, Belmont, MA |
| 2001 | Metabolism and the Atypicals: What You Need to Know, LectureFirst Annual Metro-Suburban Clinical Update, Framingham, MA |
| 2001 | Schizophrenia and Medical Morbidity, Grand RoundsBedford Veterans Administration Hospital, Bedford, MA |
| 2001 | Cross-Cultural PsychopharmacologyAdvancing the Cultural Competence CurriculumUniversity of Massachusetts Medical School, Worcester, MA |
| 2001 | Schizophrenia: Update on Antipsychotic Drugs and Metabolic Disturbances, Grand RoundsWestwood Lodge Hospital, Westwood, MA |
| 2001 | Treatment of Depression in Traumatized Refugee Populations, Grand RoundsLynn Community Mental Health Center, Lynn, MA |
| 2001 | The Use of Psychotropic Medications in Traumatized Refugee Populations, Grand RoundsLynn Community Health Center, Lynn, MA |
| 2002 | Schizophrenia, Antipsychotic Agents and Glucose MetabolismBayridge Hospital, Lynn, MA |
| 2002 | New Development in Treating Schizophrenia,Department of Veterans Affairs, Medical Center, Leeds, MA |
| 2002 | Schizophrenia and Medical Morbidity, Grand RoundsBrockton Hospital, Brockton, MA |
| 2003 | Antipsychotic: Overcoming Side Effect Treatment Barriers, Grand RoundsRiverside Clinic, Norwood, MA |
| 2003 | Antipsychotics and Schizophrenia, DiscussantBrockton Veterans Administration Hospital, Brockton, MA |
| 2003 | Antipsychotic Agents, LectureCentral Street Clinic, Somerville, MA |
| 2003 | Practical Medication Management, Workshop LectureUrban Community Psychiatry and Mental Health Practice ConferenceBoston University School of Medicine Dr. Solomon C. Fuller Mental Health Center, Boston, MA  |
| 2003 | Antipsychotic Agents and Medical Morbidity, Grand RoundsMassachusetts Mental Hospital, Boston, MA |
| 2003 | Schizophrenia and Medical Morbidity, Psychiatry Grand RoundsTufts University School of Medicine, Boston, MA |
| 2003 | Clinical Concepts in the Courtroom: Psychotic Disorders, LectureMassachusetts Continuing Legal Education, Boston, MA |
| 2003 | Practical Medicine Management, Grand RoundsSolomon Center Fuller Mental Health Center, Boston, MA |
| 2003 | The Role of Antipsychotic Therapy in Bipolar Disorder, Grand RoundsThe Institute of Living, Hartford Hospital, Hartford, CT  |
| 2004 | Aripiprazole and Clozapine, LectureLemuel Shattuck Hospital, Boston, MA |
| 2004 | Atypical Antipsychotic Agents, LectureRiverside Clinic, Norwood, MA |
| 2004 | Schizophrenia and Antipsychotic Drug, LectureAmesbury Psychological Center, Amesbury, MA |
| 2004 | Medical Morbidity and Schizophrenia, Psychiatry Grand RoundsUniversity of Massachusetts Medical School, Boston, MA |
| 2004 | Treatment of Schizophrenia, LectureGreater Lowell Psychiatric Associates, Lowell, MA |
| 2004 | Schizophrenia and Atypical AntipsychoticPennobscott Bay Medical Center, Rockport, ME |
| 2005 | Training on Psychopharmacology – Part 1Lynn Community Health Center, Lynn, MA |
| 2005 | Training on Psychopharmacology – Part 2Lynn Community Health Center, Lynn, MA |
| 2005 | Atypical Antipsychotics, Grand RoundsUnion Hospital, Lynn, MA |
| 2005 | Atypical Antipsychotic Agents and Metabolic Disturbances, Grand RoundsBaystate Medical Center, Springfield, MA |
| 2007 | Towards Global Mental Health, Grand RoundsMcLean Hospital, Boston, MA |
| 2009 | Ethnopsychopharmacology Grand RoundsNSMC Salem Hospital, Salem, MA |
| 2009 | Antipsychotic Agents and Metabolic Syndrome, Grand RoundsNorth Shore Medical Center, Salem, MA  |
| 2009 | Metabolic affects of antipsychotic drugs, Grand Rounds University of Massachusetts Medical School, Worcester, MA |
| 2011 | Chronically Mentally Ill and Medical Morbidity, Grand RoundsHarvard Longwood Psychiatry Program, Beth Israel Deaconess Medical Center, Boston, MA |
| 2011 | Mental Health and College Students, PresenterMIT Dean’s Office, Massachusetts Institute of Technology, Cambridge, MA |
| 2012 | International and Special Populations, LectureDisaster Training Course, Massachusetts Psychiatric Society |
| 2012 | Global Psychiatry in Residency TrainingHarvard Longwood Psychiatry Program, Beth Israel Deaconess Medical Center, Boston, MA |
| 2012 | Metabolic Monitoring and Atypical Antipsychotics, Grand RoundsDepartment of Psychiatry, St. Elizabeth’s Hospital, Waltham, MA |
|  |  |

### National:

|  |  |
| --- | --- |
| 1993 | Clozapine and ethnic minorities, Facilitator and Invited SpeakerFirst Annual Symposium for Mental Health Professionals of Color, Boston, MA |
| 1995 | Psychopharmacologic Issues in the Treatment of African-Americans, PresentationSecond Annual Symposium for Mental Health Professionals of Color, Boston, MA |
| 1996 | Treatment-Resistant Schizophrenia in African Americans, LectureNational Medical Association Annual Convention, Chicago, IL |
| 1996 | Mental Health in Post-War Rwanda, PresentationOrthopsychiatry Annual Conference, Boston, MA |
| 1997 | Drug Interactions with Herbal Medicines, LectureNational Medical Association Annual Convention, Honolulu, HI |
| 1997 | The Crisis in Rwanda: Mental Health in the Service of Justice and Healing, LectureNational Medical Association Annual Convention, Honolulu, HI |
| 1998 | Medical Complications of Antipsychotic Agents, LectureNational Medical Association Annual Convention, New Orleans, LA |
| 1999 | The Role of Glutamate in Schizophrenia, LectureNational Medical Association Annual Convention, Atlanta, GA |
| 2000 | Cultural Aspects of Risk Taking, LectureFifth Annual NFL Program for Substance of Abuse Treating Clinician Conference, Washington, D.C. |
| 2000 | Cultural Factors in the Treatment of African Americans, LectureThe Second Annual Luther D. Robinson, MD Symposium on Mental Health Disparities in Mental Health Access for African Americans, Washington D.C. |
| 2000 | Medical Morbidity of Antipsychotic Agents, LectureSt. Joseph’s Medical Center, Yonkers, NY |
| 2000 | Clozapine: Diabetes Mellitus, Weight Gain and Lipid AbnormalitiesNew York University School of Medicine Post Graduate Program, New York  |
| 2001 | The Use of Antipsychotic Medication Across Cultures, LectureOMH Research Conference, Albany, NY |
| 2001 | Atypical Antipsychotic Agents: Diabetes and Bergman’s Minimal Model Analysis, LectureAmerican Psychiatric Association Annual Meeting, New Orleans, LA |
| 2001 | Schizophrenia, Antipsychotic Agents and Glucose Metabolism, LectureWalter Reed Army Medical Center, Chevy Chase, MD |
| 2001 | Cultural Factors in Treatment of African-Americans, LectureBlack Psychiatrists of America 30th Anniversary Psychiatric Conference: The New Paradigms and Collaborations in Mental Health Services and Treatment for African-Americans, Atlanta, GA |
| 2001 | Antipsychotic Efficacy and Uncompromised by Side Effects, LectureNew Orleans Regional Office of Mental Health, New Orleans, LA |
| 2001 | Treatment of Schizophrenia, LectureNational Medical Association Psychiatry Annual Convention, Nashville TN |
| 2001 | Ethnopharmacology and Psychopharmacology in Special Populations, LectureUniversity of Indianapolis, Indianapolis, IN |
| 2001 | Cultural Factors in the Treatment of African-Americans, LectureAfrican American Families Living with Mental Illness: New hope, New Realities-The Mental Health Association of Alameda County, Oakland, CA |
| 2001 | Antipsychotics: Enhancing Cardiovascular and Metabolic Health, LectureAmerican Psychiatric Nurses Association (APNA), 2001 Annual Conference, Reno, NV |
| 2001 | Glucose Control and Diabetes Mellitus During Antipsychotic Treatment, Grand RoundsGorge Washington Hospital, Washington D.C. |
| 2001 | Atypical Antipsychotic Agents: Diabetes and Bergman’s Minimal Model Analysis, LectureMcGill Interactive Lecture Series in Psychiatry: New Advances in the Understanding and Management of Psychotic Disorders, New Orleans, LA |
| 2001 | Atypical Antipsychotic Agents: Update and Metabolic Disturbances, Grand RoundsHoward University School of Medicine, Washington D.C. |
| 2001 | Use of Antipsychotic Medication Across Cultures, Lecture14th Annual New York State Office of Mental Health Research Conference, Albany, NY |
| 2002 | First-Line Therapy for the Control of Psychotic DisordersUniversity of South Dakota and the South Dakota Psychiatric Society, South Dakota |
| 2002 | Schizophrenia, Antipsychotic Agents and Glucose Metabolism, LectureUniversity of South Dakota and the South Dakota Psychiatric Society, South Dakota |
| 2002 | Diabetes and the Use of Atypical Antipsychotics, Psychiatry Grand RoundsSpringfield Hospital Center, Sykesville, MD |
| 2002 | Raising Expectations in Schizophrenia: Enhancing Long-Term OutcomesAmerican Psychiatric Association Annual Conference, Philadelphia, PA |
| 2002 | Medical Comorbidity in Patients with Schizophrenia, LectureComorbid Metabolic Disturbances, New York, NY |
| 2003 | Schizophrenia Treatment in the Comminute: The Role of Long-Acting Antipsychotics, LectureAmerican Psychiatric Association Annual Meeting, San Francisco, CA |
| 2003 | Principles of Ethnopsychopharmacology, LectureAmerican Psychiatric Association Annual Meeting, San Francisco, CA |
| 2003 | Schizophrenia: Customizing Treatment Options, LectureAmerican Psychiatric Association Annual Meeting, San Francisco, CA |
| 2003 | Ethnopsychopharmacology, LectureAmerican Psychiatric Association Institute of Psychiatric Services, New York, NY |
| 2003 | Recruitment of Minority Subjects into Clinical Trials, LectureNCDEU Annual Meeting, Boca Raton |
| 2003 | Antipsychotics: Overcoming Side Effect Treatment Barriers, Neuroscience Grand Rounds 2003Friends Hospital, Philadelphia, PA |
| 2003 | Use of Antipsychotic Medication Across Cultures, Grand RoundsDepartment of Psychiatry and Behavioral Sciences, Medical University of South Carolina, SC |
| 2003 | Antipsychotics: Overcoming Side Effect Treatment Barriers, Grand RoundsGeorgia Regional Hospital, Univ. of Minnesota, Decatur, GA |
| 2003 | Schizophrenia, Antipsychotic Agents and Metabolic Disturbances, Grand RoundsSpring Grove Hospital, Catonsville, MD |
| 2003 | Antipsychotics: Overcoming Side Effect Treatment Barriers, Grand RoundsSouthwestern State Hospital, Thomasville, GA |
| 2003 | Medical Morbidity Associated with Psychotropic MedicationsSouthern New Jersey Medical Association, Cambden, NJ |
| 2003 | Schizophrenia Treatment in the Comminute: The Role of Long-Acting AntipsychoticsAmerican Psychiatric Association Annual Meeting, San Francisco, CA |
| 2003 | Schizophrenia: Customizing Treatment OptionsAmerican Psychiatric Association Annual Meeting, San Francisco, CA |
| 2003 | Principles of Ethnopsychopharmacology/Depressing and EthnopsychopharmacologyAmerican Psychiatric Association Annual Meeting, San Francisco, CA |
| 2003 | Diversity in Patient Populations and Impact on Management of Schizophrenia, Faculty LectureConference: Treating Schizophrenia in a Multicultural Population: Addressing Issues in Gender, Race and Ethnicity, UCLA Los Angeles, CA |
| 2003 | Diversity in Patient Populations and Impact on Management of Schizophrenia, LectureConference: Treating Schizophrenia in a Multicultural Population: Addressing Issues in Gender, Race and Ethnicity, UT Houston, Houston, TX |
| 2003 | Antipsychotic Efficacy Uncompromised by Disturbing Side Effects, Main SpeakerAntipsychotic Efficacy Uncompromised by Distributing Side Effects ProgramSouth Beach Psychiatric Hospital, Staten Island, NY |
| 2003 | Antipsychotic Therapy, Grand RoundsTexas Teach Medical Center, El Paso, TX |
| 2003 | Antipsychotics: Overcoming Side Effect Treatment Barriers, Grand RoundsEast Louisiana State Mental Health System, Jackson, LA |
| 2003 | Exploring the Impact of Antipsychotics on Metabolic Disturbances: Myths vs. Realities, LectureAmerican Society of Consultant Pharmacists Annual Meeting and Exhibition, San Antonio, TX |
| 2003  | Antipsychotic Therapy: Schizophrenia and Beyond, Grand RoundsSt. Louis University, St. Louis MO |
| 2003 | Pharmacologic Advance in Antipsychotic Therapy, Grand RoundsWestern State Hospital, Staunton VA |
| 2004 | First line therapy for the control of psychotic disorders: schizophrenia antipsychotic agents and glucose metabolism, LectureStanford University, Palo Alto, CA |
| 2004 | Ethnopsychopharmacology, LectureUCSF, San Francisco, CA |
| 2004 | Antipsychotic Agents and Medical Morbidity, Grand RoundsCalifornia Pacific Medical Center, Sacramento, CA |
| 2004 | Atypical Antipsychotic Agents in Diverse Populations, Grand RoundsBlack Focus Unit, San Francisco General Hospital, San Francisco, CA |
| 2004 | Atypical Antipsychotics: A Comprehensive Update, LectureSt. Joseph Outpatient Center, Syracuse, NY |
| 2004 | Sharing Clinical Decisions and Outcomes of Treating Schizophrenia, LectureUniversity of Rochester, Rochester, NY |
| 2004 | Treatment of Schizophrenia: Atypical Neuroleptic Side Effects, Weight Gain and DiabetesStrong Ties Community Support Program, Rochester, NY |
| 2004 | Comprehensive Update of the Treatment of Schizophrenia, LectureHutchings Outpatient Psych Center, Syracuse, New York |
| 2004 | Medical Morbidity, Antipsychotic Agents and Schizophrenia, LectureSt. Joseph Outpatient Center, Syracuse, New York |
| 2004 | Schizophrenia and Glucose Metabolism Impairment, Psychiatry Grand RoundsToledo Hospital, Findlay, OH |
| 2004 | Update on Antipsychotic Medications, LectureMedical College of Geriatrics Psychiatry Unit, Toledo Hospital, Toledo, Findlay, OH |
| 2004 | Psychosis and the Elderly, Grand RoundsMedical College of Ohio, Toledo Hospital, Findlay, OH |
| 2004 | Schizophrenia and Medical Morbidity, LectureDepartment of Mental Health, Dayton, Ohio |
| 2004 | Atypical Antipsychotic Agents, LectureCase Western, Cleveland, Ohio  |
| 2004 | Sharing Clinical Decisions and Outcomes of Treating Schizophrenia, LecturePen Bay Medical Center, Rockport, ME |
| 2004 | Metabolic Issues Associated with Atypical Antipsychotic AgentsDominion Psychiatric Center, Portsmouth, VA |
| 2004 | Metabolic Issues Associated with Atypical Antipsychotic AgentsChurchland Psychiatric Academy, Portsmouth, VA |
| 2004 | Metabolic Differences of Antipsychotics Among the Races, LectureAmerican Psychiatric Association (APA) Symposium: The Role of Race and Ethnicity in Utilizing Atypical Antipsychotics, Atlanta, GA |
| 2004 | Ethnopsychopharmacology Update, Paper PresentationAmerican Psychiatric Association Annual Meeting, New York, NY |
| 2004 | Clozapine and Cardiovascular Risks: Ten Year Estimates, Poster PresentationAmerican Psychiatric Association Annual Meeting, New York, NY |
| 2004 | Glucose Metabolism in Patients Treated with Atypical Antipsychotics, Poster PresentationNew Clinical Drug Evaluation Meeting 2004, Phoenix, AZ |
| 2004 | Double-Blind, Placebo Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain, Abstract PresentationAmerican Psychiatric Association Annual Meeting, New York, NY |
| 2004 | Glucose Metabolism in Patients Treated with Atypical Antipsychotics, Abstract PresentationAmerican Psychiatric Association Annual Meeting, New York, NY |
| 2004 | Long-term Outcomes of Atypical Antipsychotics, Round Table Guest SpeakerAmerican Psychiatric Association Annual Meeting, New York, NY  |
| 2004 | DSM-IV-TR Cultural Formulations: Diagnosis and Therapy, Course Developer and LectureAmerican Psychiatric Association Annual Meeting, New York, NY |
| 2004 | The use of Antipsychotic Medication Across Cultures, Psychiatry Grand RoundsMedical University of South Carolina, Charleston, SC |
| 2004 | Glucose Metabolism in Patients Treated with Atypical Antipsychotics, Poster PresentationNew Clinical Drug Evaluation Meeting 2004, Phoenix, AZ |
| 2004 | Health Disparities and Recruitment for Antipsychotic Studies, Lecture and PanelistNew Clinical Drug Evaluation Meeting 2004, Phoenix, AZ |
| 2004 | Ethnopharmacology and Psychopharmacology in Special Populations, LectureSan Francisco General Hospital, San Francisco, CA |
| 2004 | Drug-Induced Syndrome with Antipsychotics: A Paradigm Shift in Approach to Patient Care, Grand RoundsSan Francisco General Hospital, San Francisco, CA |
| 2004 | Schizophrenia and Antipsychotic Agents, Grand RoundsBerkeley Mental Health Clinic, Berkeley, CA |
| 2004 | Treatment of Psychosis, LectureEden Adult and Children Mental Health, San Leardo, CA  |
| 2004 | Treatment of Schizophrenia, Grand RoundsMission Mental Health, San Francisco, CA |
| 2004 | Antipsychotic Agents, Schizophrenia and Medical Morbidity: Impact of Ethnicity, LectureFresno County Mental Health, Fresno, CA  |
| 2004 | Antipsychotic Agents, Schizophrenia and Medical Morbidity: Impact of Ethnicity, LectureFresno County Department of Children and Family Services, Fresno, CA  |
| 2004 | Antipsychotic Agents, Schizophrenia and Medical Morbidity: Impact of Ethnicity, LecturePlace County Mental Health, Roseville, CA |
| 2004 | Antipsychotic Agents and Metabolic Disorders, LectureSutter Medical Center, Sacramento, CA |
| 2004 | The Role of Race and Ethnicity in Utilizing Atypical Antipsychotics, LectureInstitute on Psychiatric Services Symposium, Atlanta, Georgia |
| 2004 | Psychiatric Diagnosis in a Diverse Population, Grand RoundsBlack Focus Unit, San Francisco General Hospital, CA |
| 2004 | Antipsychotic Therapy, Grand RoundsUniversity of Minnesota, Minnesota, MN |
| 2004 | Antipsychotic Therapy, Grand RoundsMetropolitan State Hospital, Minnesota, MN |
| 2004 | Considerations in Long-Term Management of Schizophrenia, Grand RoundsSpring Grove Hospital Center, Catonsville, MD |
| 2004 | Pharmacological Treatment of Psychosis and Agitation in Dementia of the Elderly, Grand RoundsStanford University Medical School, Stanford, CA |
| 2004 | Drug-induced Metabolic Syndrome with Anti-Psychosis: A Paradigm Shift in Approach in Patient Care, Grand RoundsWaterbury Hospital Health Center, Waterbury, CT |
| 2004 | Considerations in Long-Term Management of Schizophrenia, Psychiatry and Behavioral Sciences, Grand Rounds Stanford University School of Medicine, Stanford, CA |
| 2004 | Health Disparities and Recruitment for Antipsychotic Studies, PresentationNew Clinical Drug Evaluation Meeting (NCDEU), Phoenix, AZ |
| 2005 | Metabolic Disturbances During Antipsychotic Treatment, Psychiatry Grand RoundsUniversity of Arizona Department of Psychiatry, Tucson, AZ |
| 2005 | Updated Therapy for Bipolar Disorders, LectureDesert Vista Hospital, Phoenix, AZ |
| 2005 | DSM-IV-TR Cultural Formulations: Diagnosis and Therapy, Course Developer and LectureAmerican Psychiatric Association Annual Meeting, Atlanta, GA |
| 2005 | Polypharmacy in Schizophrenia Treatment, Paper PresentationAmerican Psychiatric Association Annual Meeting, Atlanta, GA |
| 2005 | Ethnopsychopharmacology: An Update on Cross-Cultural Aspects of Mood and Anxiety Disorders, Paper PresentationAmerican Psychiatric Association Annual Meeting, Atlanta, GA |
| 2005 | Ethnopsychopharmacology, Psychiatry Grand RoundsHoward University Hospital, Washington, D.C. |
| 2005 | Assessing the Risk of Metabolic Syndrome in Psychiatric Illness When Adding Atypical Antipsychotics to the Equation, Lecture and Roundtable ParticipantRoundtable: Endocrine and Metabolic Distributes in Psychiatric Disorders: A Multi-Specialty Approach to Appropriate Atypical Antipsychotic Selection, Atlanta, Georgia |
| 2005 | Metabolic Consequences in the Treatment of Mood Disorders, Lecture and PanelistNational Medical Association (NMA) Scientific Assembly, Houston, TX |
| 2005 | Treatment of First Episode Schizophrenia: Can We Change the Course of the Illness, Monthly Lecture Series Lecture (100+ persons)Milwaukee County Department of Health & Human Services, Behavioral Health Division Milwaukee, WI |
| 2005 | Antipsychotic Initiation, Titration, and Switching: Clinical Considerations for Optimizing Therapy, Advisory Board Faculty LectureChicago, IL |
| 2005 | Antipsychotic agents and medical comorbidity, Psychiatry Grand RoundsNew Jersey VA Healthcare System, East Orange, NJ |
| 2005 | Metabolic Disturbances During Antipsychotic Treatment, Grand RoundsPuget Sound Health Care System, Tacoma, WA |
| 2005 | The Etiology of the Metabolic Syndrome, Faculty Member and PresenterU.S. Psychiatric and Mental Health Congress, Las Vegas, NV |
| 2005 | Stable Patients: Optimal Dosing and Switching, LectureAntipsychotic Initiation, Titration, and Switching: Clinical Considerations for Optimizing Therapy, Advisory Board Meeting, Washington, DC |
| 2006 | Predicting Adverse Events Based on Pharmacological Profiles, LectureAn Evidence-based Approach to Optimizing Functionality in Patients with Psychotic Disorders Symposium, UCLA Los Angeles, California |
| 2006 | Exploring the Pharmacodynamics of Atypical Antipsychotics: Focus on Safety, Presenter and Host, Practical Psychopharmacology Update Series, U.S. Psychiatric & Mental Health Congress, San Francisco, CA |
| 2006 | Comorbid Metabolic Disturbances in the Mentally Ill, LectureNational Forum on Medical Comorbidities and Metabolic Disturbances in the Mentally IllUCLA School of Management, Los Angeles, CA |
| 2006 | Exploring the Pharmacodynamics of Atypical Antipsychotics: Focus on Safety, Host and Presenter, Practical Psychopharmacology Update Series, U.S. Psychiatric & Mental Health Congress, Dearborn, MI |
| 2006 | Evaluating the Pharmacology of Atypical Antipsychotics: Implications on Safety and Tolerability, Lecture15th Annual Practical Psychopharmacology Conference of the U.S. Psychiatric and Mental Health Congress, Palm Beach, FL |
| 2006 | Comorbid Metabolic Disturbances in the Mentally Ill, Lecture Practical Psychopharmacology Update Series: National Forum on Medical Comorbidities and Metabolic Disturbances in the Mentally Ill Symposium, U.S. Psychiatric & Mental Health Congress, Chicago, IL |
| 2006 | Evaluating the Pharmacology of Atypical Antipsychotics: Implications on Safety and Tolerability, Lecture15th Annual Practical Clinical Psychopharmacology Meeting Series, Las Vegas, NV |
|  2006 | Evaluating the Pharmacology of Atypical Antipsychotics: Implications on Safety and Tolerability, Lecture15th Annual Practical Clinical Psychopharmacology Meeting Series, Del Ray, FL |
| 2006 | Pharmacogenetics of Weight Gain Associated with Atypical Anti-psychotics in African Americans, LectureNational Medical Association National Conference, Honolulu, Hawaii |
| 2006 | Treating Diverse Populations in Bipolar Disorder: Focus on Safety and Efficacy, Lecture19th Annual U.S. Psychiatric & Mental Health Congress: Identifying Ethnic and Cultural Diversity in Bipolar: Pathways to Improving the Care of Patients Symposium, New Orleans, LA |
| 2006 | Ethnopsychopharmacology: An Update, LectureDSM-IV-TR Cultural Formulations: Diagnosis and Therapy, APA Institute on Psychiatric Services Conference, New York, NY |
| 2006 | Exploring Strategies to Improving Remission Rates: How and When to Switch Therapies, Presentation, Lecture Improving Wellness and Functionality: The Role of Atypical Antipsychotics Series, UT Southwestern, Dallas, TX  |
| 2007 | Long-term Management of Psychotic Disorders: The Road to Recovery, Lecture and PresenterAn Evidence-based Approach to Optimizing Functionality in Patients with Psychotic Disorders Symposium, Miami, Florida  |
| 2007 | Ethnopsychopharmacology, Psychiatry Grand RoundsHoward University Medical School, Washington, DC |
| 2007 | Obesity and Mental Illness, Lecture Psychiatric Comorbidities in Medical Disorders Conference, American Academy of Clinical Psychiatrists Annual Meeting, Washington, DC |
| 2007 | Ethnopsychopharmacology, Psychiatry and Behavioral Sciences Grand RoundsSaint Vincent Catholic Medical Centers and New York Medical College, New York, NY |
| 2007 | DSM-IV-TR Cultural Formulations: Diagnosis and Treatment, LectureAmerican Psychiatric Association Annual Meeting, San Diego, CA |
| 2007 | APA’s Solomon Carter Fuller Award LectureAmerican Psychiatric Association Annual Meeting, San Diego, CA |
| 2007 | An Update on Cross-Cultural, Ethnic, and Ethnopsychopharmacological Aspects of Mood Disorders, PresentationAmerican Psychiatric Association Annual Meeting, San Diego, CA |
| 2007 | Considerations in the Health Management of Patients with Schizophrenia, Symposium Lecture and PanelPRIME, Inc., Denver, CO  |
| 2007 | The Safety of Atypical Antipsychotics, Lecture and PanelistLinking Pharmacology to Clinical Management: Improving Long-Term Outcomes with Atypical Antipsychotics Meeting Series, New York, NY  |
| 2008 | Schizophrenia vs. Schizoaffective Disorder: Individualizing Treatment Plans and Understanding Non-adherence, LectureSchizophrenia vs. Schizoaffective Disorder: Clinical Implications for Therapeutic Decisions Symposium, U.S. Psychiatric & Mental Health Congress, San Diego, CA  |
| 2009 | Treating Depression in Latinos/Hispanic: Culture, Ethnopharmacology and Availability, LectureRecognition and Management of Depression and Co-Morbidities in Hispanic Communities Curriculum, National Hispanic Medical Association, Brooklyn, NY  |
| 2009 | Exposure to Community Violence, PresenterAging and Disability Resource Center (ADRC) of the US Dpt. of Health and Human Services Conference, Hartford, CT |
| 2009 | Antipsychotic drugs and glucose metabolism, Keynote SpeakerAnnual Dewitt C. Alfred, Jr., M.D. Psychiatric Research Symposium, Department of Psychiatry and Behavioral Sciences, Morehouse School of Medicine, Atlanta, GA |
| 2009 | Cross Cultural Psychiatry, Grand RoundsMental Health Grand Rounds Training for Santa Clara County, San Jose, CA |
| 2009 | Schizophrenia and Metabolic Disorders, Ken Z. Altschuler, MD Grand Rounds in PsychiatryUniversity of Texas Southwestern Medical Center, Dallas, TX |
| 2010 | Implementation Research Experience from the Field, PresenterOn the Pulse of Global Mental Health Action: Identifying Strategic Research Opportunities Conference, NIH/NIMH, Bethesda, MD |
| 2010 | Ethnopsychopharmacology, Grand RoundsBeth Israel Medical Center, New York, NY |
| 2010 | Need for Global Psychiatric Help, Chief Guest AddressInternational Medical Health Organization Annual Convention, Boston, MA |
| 2010 | Schizophrenia Update, LectureNational Medical Association Annual Convention, Orlando, FL |
| 2010 | Ethnopsychopharmacology, LectureNational Medical Association Annual Convention, Orlando, FL |
| 2010 | Disasters, conflict and trauma, LectureNational Medical Association Annual Convention, Orlando, FL |
| 2010 | Overcoming Cognition Barriers for Early and Proper Diagnosis, Appropriate Treatment of Schizophrenia and Mood Disorders in African American and Other Minority Populations and Side Effect Management, Particularly Weight Gains, Lecture16th Annual Convention and Scientific Assembly, Association of Nigerian Physicians in the Americas, Prince George County, MD |
| 2010 | Measuring Lipids in Patients with Bipolar Disorder: Why We Have To, LectureNeuroscience Television Broadcast, Washington, DC |
| 2011 | Improving Wellness and Functionality: The Role of Atypical Antipsychotics, LectureExploring Strategies to Improving Remission Rates: How and When to Switch TherapiesDepartment of Mental Health, San Jose, California |
| 2011 | Ethnopsychopharmacology, Psychiatry Grand RoundsBeth Israel Medical Center, New York, NY |
| 2011 | Psychopharmacology: Does Ethnicity Matter? A Global Perspective, Grand RoundsColumbia University, New York, NY |
| 2011 | Risk of Diabetes in People with Mental Illness, Diabetes Broadcast (National Radio)San Diego, CA |
| 2011 | Antipsychotics and Medical Morbidity, Grand Rounds Naomi Berrie Diabetes Center, Columbia University Medical Center, New York, NY |
| 2011 | Mental Health and Non-Communicable Diseases, Presenter and Meeting co-OrganizerYoung Professionals Non-Communicable Disease Mental Health Work Group: Pre- UN-Summit Meeting, Cornell Medical School, New York, NY |
| 2012 | Different Faces of Global Mental Health, Workshop PanelistAmerican Psychiatric Association Annual Meeting, Philadelphia PA |
| 2012 | Ethnopsychopharmacology Update, PresenterAmerican Psychiatric Association Annual Meeting, Philadelphia, PA |
| 2013 | Ethnopsychopharmacology, Psychiatry Grand RoundsUNC Chapel Hill, North Carolina |

**International:**

|  |  |
| --- | --- |
| 2000 | Healing and Recovering of Cambodia, LectureThe Italian Society of Medicine and Migrations, Rome, Italy |
| 2001 | Atypical Antipsychotic Agents: Diabetes and Bergman’s Minimal Model Analysis, LectureWorld Congress of Biological Psychiatry Annual Meeting, Berlin, Germany |
| 2001 | Atypical Antipsychotic Agents: Diabetes and Bergman’s Minimal Model Analysis, LectureClinical Investigators in Neuropsychiatry, Hiroshima, Japan |
| 2001 | Antipsychotic Agents: Efficacy and Medical Morbidity, LectureShimofusa Mental Hospital, Hiroshima, Japan |
| 2003 | Efficacy, Safety and Tolerability of Evolving Atypical Antipsychotic Agents, LectureKorean Neuropsychiatric Association Annual Meeting, Seoul, South Korea |
| 2003 | Schizophrenia: Treatments for Cognitive and Negative Symptoms, Grand RoundsHospital Asan, Seoul, South Korea |
| 2004 | Glucose Metabolism in Schizophrenia Patients Treated with Atypical Antipsychotic: A Frequent Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis, LectureWorld Congress Biological Psychiatry Conference, Sydney, Australia |
| 2004 | Clinical Issues and Ethnopsychopharmacology, LectureInternational Conference on Culture and Mental Health, Manchester, UK |
| 2004 | Treatment of Schizophrenia, LectureOmagari Hospital, Akita, Japan |
| 2004 | Glucose Metabolism and Schizophrenia, LectureHamamatsu University School of Medicine, Hamamatsu, Japan |
| 2004 | Diabetes, Schizophrenia and Minimal Model Analysis, LectureHokuto-kaiSawa Hospital, Shinosaka, Japan |
| 2004 | EthnopsychopharmacologyOsaka Keisatsu Hospital Osaka, Japan |
| 2004 | Medical Morbidity and Schizophrenia, LectureHatsuishi Hospital, Chiba, Japan |
| 2004 | Schizophrenia and Medical Morbidity, LectureSaiseikai Matsukaze Hospital, Shizuoka, Japan  |
| 2004 | Treatment Approach for Schizophrenia, LectureAsahikawa Medical College, Asahikawa, Japan |
| 2005 | A Comparison of the Effects of Quetiapine and Olazapine on Glucose Metabolism in Patients with Schizophrenia, Poster Presentation18th European Congress of Neuropsychopharmacology, Amsterdam, Netherlands |
| 2006 | Antipsychotic Drugs, Obesity and Diabetes, PresenterInternational Diabetes Federation’s 19th World Diabetes Congress, Cape Town, South Africa |
| 2006 | Sponsored Participant, Second Action Planning Conference for Iraq Mental HealthSubstance Abuse and Mental Health Services Administration, Cairo, Egypt |
| 2008 | Improving Adherence: How Far Have We Come? Lecture 21st ECNP Congress, Promoters and Barriers to Adherence and Overall Health Status in Patients with Serious Mental Illness,Barcelona, Spain |
| 2010 | Management of Schizophrenia and Metabolic Syndrome, Keynote Grand Rounds Lecture Sultan Abdul Halim Hopsital, Kedah, Malaysia |
| 2010 | Antipsychotic Agents and Ethnicity in Malaysia, Grand Rounds LectureSultan Abdul Halim Hospital, Kedah, Malaysia |
| 2010 | Schizophrenia & Metabolic Syndrome, Keynote Grand Rounds LectureHospital Bahagia Ulu Kinta Perak DarulRidzuan (HBUK), Tanjung Rambutan, Malaysia |
| 2012 | No Health Without Mental Health: Policy and Practice in KuwaitWorld Mental Health Day 2012, Kuwait City, Kuwait |
| 2012 | Psychiatry 101: Key Concepts to Advance Patient Well-beingWorld Mental Health Day 2012, Kuwait City, Kuwait |
| 2012 | Ask the Psychiatry Experts PanelWorld Mental Health Day 2012, Kuwait City, Kuwait |
| 2012 | Obesity, Diabetes and Mental HealthWorld Mental Health Day 2012, Kuwait City, Kuwait |
| 2012 | Reducing the Mental Health StigmaWorld Mental Health Day 2012, Kuwait City, Kuwait |
| 20122013 | Enhancing Integration of Health and Mental Health Services in KuwaitWorld Mental Health Day 2012, Kuwait City, KuwaitThe role of inflammation in schizophreniaSouth African Biological Psychiatry, Durbin South Africa |

**Report of Clinical Activities and Innovations**

**Clinical Innovations:**

|  |  |
| --- | --- |
| **Clozapine Clinic for Treatment-resistant psychosis at MGH and the Freedom Trail Clinic (1992)** | Developed a comprehensive specialty program for treatment-resistant psychosis provide one-stop care where all activities related to monitoring of the white blood cells, psychopharmacology appointments, therapy and delivery of the clozapine during one the same visit to the clinic was implemented. This Clozapine Clinic continues to be one of the largest in the country, and has served as a training site for medical students, residents and clinicians locally, Nationally and Internationally. |
| **Clozapine Metabolic Syndrome Monitoring at MGH and the Freedom Trail Clinic (1993)** | Developed a monitoring system for clozapine-treated patients to identify individuals at risk and early detection of diabetes mellitus and cardiovascular disease. This system, which is still utilized today, resulted in a robust research program, numerous publications and presentations locally, nationally and internationally and played a major role the development of guidelines for monitoring of atypical antipsychotic agents for weight, lipids, and glucose |
| **Integration of mental health care into primary care medicine in Cambodia (1996)** | Team member and investigator in a program to integrate mental health care into primary care medicine in Cambodia. Trained 100 primary care physicians from all of the country over a two-year period. |
| **Integration of mental health care into primary care medicine in Bosnia Herzegovina (1998)** | Team member and investigator in a program to integrate mental health care into primary care centers in postwar Bosnia Herzegovina. This program was adapted and utilized throughout the region. |
| **Wellness Consultation Program at MGH (2005)** | Developed a comprehensive consultation program for patients treated with antipsychotic drug to assess their metabolic risk, and develop recommendations to reduce their risk. |
| **Healthy Lifestyle Program at MGH and the Freedom Trail Clinic (2006)** | Developed Weight-reduction nutrition and exercise program for patient with mental illness utilizing modest lifestyle modification, nutritional consultation, and mentored exercise programs |
| **Integration of mental health care into primary care medicine in Peru (2006)** | Team member and developer of a program to train and provide ongoing supervision to 52 primary care clinicians in Peru to integrate mental health care and provide mental health care to remote areas in Peru. The program resulted in the government of Peru implementing this program throughout the country |
| **The Coordinated Health and Medical Prevention Service (CHAMPS) at MGH and the Freedom Trail Clinic (2012)** | CHAMPS serves tointegrate and coordinate the medical care for patients with schizophrenia andemphasizes prevention via appropriate medical monitoring and screening.CHAMPS also serves as a platform for better longitudinal integration betweenyoung, first-episode patients treated at MGH and multi-episode patientstreated at the Freedom Trail Clinic. Role: Mentor |

**Report of Education of Patients and Service to the Community**

[Activities](http://cv.hms.harvard.edu/index.php?page=activities):

|  |  |
| --- | --- |
| 1992- | Church Organizations, MIT community, college courses |
|  | Lectures to community groups on mental health |
| 1997- | American Red Cross |
|  | Volunteer, Disaster Response |
| 2001 | Congregation Kehillath Israel |
|  | Lectures to the organization “Refuah” |
| 2005 | American Red Cross |
|  | Hurricane Katrina relief effort, received a certificate of appreciation  |
| 2007 | Lectures to the church members in Boston, MA |
| 2009 | Lectures to the St. Paul’s Church members in Cambridge, MA |
| 2011 | Topic Lectures to the Eleventh Baptist Church members in Roxbury, MA |

**Bibliography**

[**Peer reviewed publications in print or other media**](http://cv.hms.harvard.edu/index.php?page=peer_review)**:**

**Original Research:**

|  |
| --- |
| 1. Goff DC, **Henderson DC**, Amico E: Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry 1992; 149:1189-1194.
2. **Henderson DC**, Goff DC: Clozapine for polydipsia and hyponatremia in chronic schizophrenics. Biol Psychiatry 1994; 36:768-770.
3. **Henderson DC,** Goff DC: Risperidone as adjunct to clozapine treatment in treatment- refractory schizophrenics. J Clin Psychiatry 1996; 57: 395-397.
4. **Henderson DC**, Nasrallah RA, Goff DC: Switching from clozapine to olanzapine in treatment refractory schizophrenia: safety, clinical efficacy and predictors of response. J Clin Psychiatry 1998;59:585-588.
5. Goff DC, **Henderson DC**, Evins AE, Amico E: A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 1999;45:512-514.
6. **Henderson DC**, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five year naturalistic study. Am J Psychiatry 2000;157:975-981.
7. Frankle WG, Shera D, Berger-Hershkowitz H, Evins AE, Connolly C, **Henderson DC**. Clozapine associated reduction in arrest rates of psychotic patients with criminal histories. Am J. Psychiatry 2001; 158: 270-274.
8. **Henderson DC,** Goff DC, Connolly C, Borba CP. Risperidone added to clozapine: Impact on serum prolactin levels. J Clin Psychiatry 2001; 62: 605-608.
9. Mollica RF, **Henderson DC**, Tor S. Psychiatric effects of traumatic brain injury events in Cambodian survivors of mass violence. Br J Psychiatry 2002; 181:339-347.
10. **Henderson DC**, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psych. 2004;65:686-689.
11. Evins AE, Cather C, Freudenreich O, **Henderson DC**, Olm-Shipman CM, Goff DC. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry. 2004; 65:307-311.
12. Freudenreich O, Cather C, Evins AE, **Henderson DC**, Goff DC. Attitudes of schizophrenia outpatients towards psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry 2004; 65(10):1372-1376
13. Goff DC, Bottiglieri T, Arning E, Shik V, Freudenreich O, Evins AE, **Henderson DC**, Baer L, Coyle J. Folate, homocysteine, and negative symptoms in schizophrenia. Am J Psychiatry 2004; 161(9):1705-1708
14. Goff DC, Herz L, Posever T, Shih V, Tsai G, **Henderson DC**, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D: A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005; 179(1):144-150
15. **Henderson DC,** Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC: Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62(1):19-28
16. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, **Henderson DC**, Schoenfeld DA, Goff DC, Rigotti NA: A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J ClinPsychopharmacol 2005; 25(3):218-225
17. **Henderson DC**, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, Evins AE, Freudenreich O, Hayden D, Goff DC: A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated with weight gain. Am J Psychiatry 2005; 162(5):954-962.
18. **Henderson DC,** Mollica RF, Tor S, Lavelle J, Culhane MA, Hayden D: Building primary care practitioners' attitudes and confidence in mental health skills in a post-conflict society: A Cambodian example. J Nerv Ment Dis 2005; 193(8):551-559
19. **Henderson DC,** Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, Goff DC: Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66(9):1116-1121
20. Freudenreich O, Herz L, Deckersbach T, Evins AE, **Henderson DC**, Cather C, Goff DC: Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2005; 181(2):358-363
21. Evins AE, Deckersbach T, Cather C, Freudenreich O, Culhane MA, **Henderson DC**, Green MF, Schoenfeld DA, Rigotti NA, Goff DC: Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry 2005; 66(9):1184-1190
22. **Henderson DC,** Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, Freudenreich O, Cather C, Evins AE, Goff DC: An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006; 113(2):142-147
23. **Henderson DC,** Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA, Louie PM, Cather C, Evins AE, Freudenreich O, Taber SM, Goff DC. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry 2006; 18(2):99-105
24. **Henderson DC,** Copeland PM, Nguyen DD, Borba CP, Cather C, Eden Evins A, Freudenreich O, Baer L, Goff DC: Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. Acta Psychiatr Scand 2006; 113(2):121-5
25. **Henderson DC**, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H , Hayden D, Freudenreich O, Cather C, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006; 67(5):789-797
26. Weiss AP, **Henderson DC**, Weilburg JB, Goff DC, Meigs JB, Cagliero E, Grant RW. Treatment of cardiac risk factors in patients with schizophrenia and diabetes. Psychiatr Serv 2006;57(8):1145-1152
27. Weiss AP, Goff DC, Schacter DL, Ditman T, Freudenreich O, **Henderson DC**, Heckers S. Fronto-hippocampal function during temporal context monitoring in schizophrenia. Biol Psychiatry. 60:1268-1277.
28. Fan X, Liu EY, Pristach C, Goff DC, **Henderson DC**. Higher fasting serum insulin is associated with a better psychopathology profile in acutely ill non-diabetic inpatients with schizophrenia. [Schiz Res.](http://www.ncbi.nlm.nih.gov/pubmed/16750348) 2006 Sep;86(1-3):30-35. Epub 2006 Jun 5.
29. Fan X, Anderson EJ, Copeland PM, Borba CP, Nguyen DD, Freudenreich O, Goff DC, **Henderson DC**. Higher fasting serum insulin is associated with increased resting energy expenditure in non-diabetic schizophrenia patients. Biol Psychiatry. 2006;60:1372-1377.
30. Fan X, Pristach C, Liu EY, Freudenreich O, **Henderson DC**, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res, 2007; 149:267-271.
31. **Henderson DC**, Cagliero E, Copeland PM, Louie PM, Borba CP, Fan X, Freudnereich O, Goff DC. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 2007; 68:533-541.
32. Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, **Henderson DC**, Purcell S, Wong DH, Halsted CH, Goff DC. Effects of the methylenetetrahydrofolatereductase (MTHFR) C677T polymorphism on executive function in schizophrenia.  Schizophr Res. 2007 May;92(1-3):181-188.
33. **Henderson DC**, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D,Freudenreich O, Cather C, Eden Evins AE, Goff DC. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007; 115(2):101-115.
34. Freudenreich O, **Henderson DC**, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled trial. Schizophr Res. 2007;92(1-3):90-49
35. Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, Freudenreich O, **Henderson DC**, Schoenfeld DA, Rigotti NA, Goff DC. A 12-week double blind, placebo-controlled study of bupropion slow release added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clinical Psychopharmacol. 2007 Aug; 27(4):380-386.
36. Fan X, **Henderson DC**, Chiang E, Briggs LB, Freudenreich O, Evins AE, Cather C, Goff DC. Sexual functioning, psychopathology, and quality of life in patients with schizophrenia. Schizophr Res. 2007 Aug; 94(1-3):119-127.
37. Freudenreich O, Gandhi RT, Walsh JP, **Henderson DC**, Goff DC. Hepatitis C in schizophrenia: Screening experience in a community-dwelling clozapine cohort. Psychosomatics 2007 Sep-Oct; 48(5):405-411.
38. Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, **Henderson DC**, Bottiglieri T, Wong DH, Halsted CH, Goff DC. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative Symptoms in Schizophrenia. Biol Psychiatry 2008; 63(1):42-48.
39. Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, **Henderson DC**, Wong DH, Halsted CH, Goff DC. Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2008 147B(6):990-5.
40. [Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, **Henderson DC**, Purcell S, Wong DH, Halsted CH, Goff DC. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia.](http://www.ncbi.nlm.nih.gov/pubmed/17344026) Schizophr Res. 2007 May;92(1-3):181-188. Epub 2007 Mar 6.
41. **Henderson DC**, Kapetanovic A, Culhane MA, Lavelle J, Miley K, Gray DG, Borba CP, Mollica RF. Building primary care practitioners’ attitudes and confidence in mental health skills in post-conflict Bosnia and Herzegovina. International Journal of Culture and Mental Health. 2008; 1(2) 117-133.
42. Oruc L, Kapetanovic A, Pojskic N, Miley K, Mollica RF, **Henderson DC**. Screening for PTSD and depression in Bosnia and Herzegovina: Validating the Harvard Trauma Questionnaire and the Hopkins Symptom Checklist. Int J Culture and Mental Health. December 2008; 1(2): 105-116.
43. Fan X, **Henderson DC**, Nguyen DD, Cather C, Freudenreich O, Evins AE, Borba CP, Goff DC: Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. Psychiatry Res 2008; 159(1-2):140-146.
44. Rumala BA, Fan X, Sharma B, Nguyen DD, Borba CPC, Briggs LBN, Forstbauer S, Miley K, **Henderson DC**. Waist Circumference does not predict insulin resistance in African American schizophrenia patients. Int J of Culture and Mental Health. December 2008; 1(2): 93-104.
45. **Henderson DC**, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC. A double blind, placebo- controlled trial of rosiglitazone for clozapine induced glucose metabolism impairment in patients with schizophrenia. ActaPsychiatr Scand. 2009 Jun;119(6):457-65.
46. Freudenreich O, **Henderson DC**, Macklin EA, Evins AE, Fan X, Cather C, Walsh JP, Goff DC. Modafinil for clozapine-treated schizophrenia patients. A double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 Dec;70(12):1674-1680.
47. **Henderson DC**, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol. 2009 Apr;29(2):165-169.
48. **Henderson DC**, Fan X, Sharma B, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC. Waist Circumference is the best anthropometric predictor for insulin resistance in non-diabetic clozapine-treated schizophrenia patients but not olanzapine. J Psychiatr Pract. 2009 Jul;15(4):251-261.
49. **Henderson DC**, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, Miley K, Boxill R, Freudenreich O, Cather C, Evins AE, Goff DC. Ziprasidone as an adjuvant for clozapine- or olanzapine- associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol. 2009; 24(3):225-232.
50. Goff DC, Cather C, Freudenreich O, **Henderson DC,** Evins AE, Culhane MA, Walsh JP. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology (Berl). 2009; 202(1-3):411-417.
51. Freudenreich O, Brockman M, **Henderson DC,** Evins AE, Fan X, Walsh JP, Goff DC. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). Psychiatry Res. 2010;176(2-3):99-102.
52. **Henderson DC**, Sharma B, Fan X, Copeland PM, Borba CP, Freudenreich O, Cather C, Evins AE, Goff DC. Dietary saturated fat intake and glucose metabolism impairments in non-diabetic non-obese patients with schizophrenia on clozapine or risperidone. Ann Clin Psychiatry. 2010 Feb;22(1):33-42.
53. Fan X, Liu EY, Freudenreich O, Park JH, Liu D, Wang J, Yi Z, Goff D, **Henderson DC.** [Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia.](http://www.ncbi.nlm.nih.gov/pubmed/20189773) Schizophr Res. 2010;118(1-3):211-7.
54. Wang J, Freudenreich O, Goff D, **Henderson DC**, Fan X. Phenotypic characteristics in metabolically obese but normal weight non-diabetic patients with schizophrenia. Schizophr Res. 2010; 124 (1-3): 49-53.
55. Fan X, Copeland P, Liu EY, Chiang E, Freudenreich O, Goff D, **Henderson DC**. No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia. J Clin Psychopharmacology. 2011; 31 (2): 231-234.
56. Fan X, Liu EY, Hoffman VP, Potts AJ, Sharma B, **Henderson DC**. [Triglyceride/high-density lipoprotein cholesterol ratio: a surrogate to predict insulin resistance and low-density lipoprotein cholesterol particle size in nondiabetic patients with schizophrenia.](http://www.ncbi.nlm.nih.gov/pubmed/21208572) J Clin Psychiatry. 2011 Jun;72(6): 806-812. Epub 2010 Nov 2.
57. Harris BL, Levey EJ, Borba CPC, Gray DA, Carney JR, **Henderson DC**.  Substance use behaviors of secondary school students in post-conflict Liberia: A pilot study. Int J Culture and Mental Health, 2012; 5(3): 190-201.
58. **Henderson DC**, Freudenreich O, Borba CPC, Wang X, Copeland PM, Macklin E, Fan X, Cather C, Goff DC. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. Schizophrenia Res 2011 Aug;130(1-3); 53-56. Epub 2011 May 11.
59. Tranulis C, **Henderson DC**, Freudenreich O, Goff DC. Becoming adherent to antipsychotics: a qualitative study of treatment-experienced schizophrenia patients. Psychiatric Services 2011 Aug;62(8): 888-892.
60. Borba CPC, Fan X, Copeland PM, Paiva A, Freudenreich O, **Henderson DC**. Placebo-controlled pilot study of ramelteon for adiposity and lipids in patients with schizophrenia. J Clin Psychopharmacology. 2011; 31 (5): 653-658.
61. Wiechers I, Freudenreich O, Weiss A, **Henderson DC**, Viron M, Stoklosa J. Impact of metabolic screening bundle on rates of screening for metabolic syndrome in a psychiatry resident outpatient clinic. Academic Psychiatry 2012; 36:118-121.
62. Zhenghui Y, Xiaoduo F, JiJun W, Dengtang L, Freudenreich O, GoffD, **Henderson DC.** Rosiglitazone and cognitive function in clozapine treated patients with schizophrenia: A pilot study. Psychiatry Res. 2012 Dec 30;200(2-3):79-82.
63. WangJ, Fan X, Liu D, Yi, Z, Freudenreich O, Goff DC, **Henderson DC**. Both physical activity and food intake are associated with metabolic risks in patients with schizophrenia. Schizophr Res. 2012 Sep;140(1-3):260-261.
64. Yi Z, Fan X, Wang J, Liu D, Freudenreich O, Goff D, **Henderson DC**. [Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study.](http://www.ncbi.nlm.nih.gov/pubmed/22727707) Psychiatry Res. 2012 Dec 30;200(2-3):79-82.
65. Dominguez S, Borba C, Fatima B, Gray D, Stinehart C, Murphy G, Wang E, Harris B, **Henderson DC**. Mental health and adaption of young Liberians in post-conflict Liberia: a key informant’s perspective. Int J Culture and Mental Health, 2012: 1-17.
66. Fan X, Borba CP, Copeland P, Hayden D, Freudenreich O, Goff DC, **Henderson DC.** Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand. 2013 Mar;127(3):217-26.
67. Fan X, Liu E, Freudenreich O, Copeland P, Hayden D, Ghebremichael M, Cohen B, Ongur D, Goff DC, **Henderson DC**. No effect of adjunctive, repeated dose intranasal insulin treatment on psychopathology and cognition in patients with schizophrenia. J Clin Psychopharmacology. 2013 Apr;33(2):226-30.Li J, Li X, Liu E, Copeland P,
68. Freudenreich O, Goff DC, **Henderson DC**, Song X, Fan X. No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia. Schiz Research. 2013 May;146(1-3):40-5. doi:10.1016/j.schres.2013.01.034. Epub 2013 Feb 21.
69. Levey EJ, Borba CPC, Harris BL, Carney JR, Domínguez S, Wang EKS, Boxill R, **Henderson DC**. Assessment of the needs of vulnerable youth populations in post-conflict Liberia. African J of Psych. 2013 Sep;16(5):349-55.
70. Vincenzi B, Borba CPC, Gray DA, Copeland PM, Wang X, Fan X, Aragam GG, **Henderson DC.** An exploratory study examining lipid lowering medications in reducing fasting serum lipids in patients with schizophrenia treated with atypical antipsychotic medications. Ann Clin Psychiatry. 2013 May;25(2):141-8.
71. Gray DA, Borba CPC, Harris BL, Domínguez S, Boxill R, Wang EKS, **Henderson DC**. Understanding Cohort Differences in Appraisals of Reconstruction Priorities of Mental Health Systems in Post-Conflict Liberia. African J of Psych. 2013 Nov 19;16(6).
72. Thakurathi N, Stock S, Oppenheim CE, Borba CPC, Vincenzi B, Seidman LJ, Stone WS, **Henderson DC**. Open-label pilot study of vitamin d3 supplement for antipsychotic-associated metabolic anomalies. Int Clin Psychopharmacol. 2013 Sep;28(5):275-82. doi: 10.1097/YIC.0b013e3283628f98. PMID: 23694999
73. [Fekadu A, Mesfin M, Medhin G, Alem A, Teferra S, Gebre-Eyesus T, Seboxa T, Assefa A, Hussein J, Lemma MT, Borba C, **Henderson DC**, Hanlon C, Shibre T. Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial.](http://phstwlp1.partners.org:2111/pubmed/24279305) Trials. 2013 Nov 27;14:406. doi: 10.1186/1745-6215-14-406. PMID: 24279305
74. Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA, Stroup TS; **METS Investigators**. [Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.](http://phstwlp1.partners.org:2111/pubmed/23846733) Am J Psychiatry. 2013 Sep 1;170(9):1032-40. doi:10.1176/appi.ajp.2013.12010127. PMID: 23846733
75. Amatniek J, Canuso CM, Deutsch S, **Henderson DC**, Mao L, Mikesell C, Rodriguez S, Sheehan J, Alphs L. [Safety of Paliperidone Extended-release in Patients with **Schizophrenia** or Schizoaffective Disorder and Hepatic Disease.](http://phstwlp1.partners.org:2111/pubmed/23428785) Clin Schizophr Relat Psychoses. 2013 Feb 21:1-47. [Epub ahead of print] PMID: 23428785
 |

1. Quiterio N, Harris BL, Borba CPC, **Henderson DC**. Substance Use and Sexual Risk Behaviors amongst In-school Youth and Young Adults Living in Liberia. African Journal of Drug and Alcohol Studies. 2013; 12(2): 75-91.
2. Zhong Q, Gelaye B, Rondon M, Sánchez SE, García PJ, Sánchez E, Barrios YV, Simon GE, **Henderson DC**, Cripe SM, Williams MA. Comparative performance of Patient Health Questionnaire-9 and Edinburgh Postnatal Depression Scale for screening antepartum depression. J Affect Disord. 2014 Jun;162:1-7.
3. Zhong Q-Y, Gelaye B, Rondon MB, Sánchez SE, Simon GE, **Henderson DC**, Barrios,Sánchez PM, Williams WA Using the Patient Health Questionnaire (PHQ-9) and the Edinburgh Postnatal Depression Scale (EPDS) to assess suicidal ideation among pregnant women in Lima, Peru. Arch Womens Ment Health. 2014 Nov 5.
4. Vincenzi B, Stock S, Borba CPC, Cleary SM, Oppenheim CE, Petruzzi LJ, Fan X, Copeland PM, Freudenreich O, Cather C. **Henderson DC**. A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism. Schizophrenia Research. Schizophr Res. 2014 Sep 25.
5. Borba CPC, Gelaye B, Zayas L, Ulloa M, Lavelle J, Mollica RF, **Henderson DC**. Making strides towards better mental health care in Peru: Results from a primary care mental health training. International Journal of Clinical Psychiatry and Mental Health. 2015 Apr 30.
6. Gelaye B, Barrios YV, Zhong Q, Rondon MB, Borba CPC, Sánchez SE, **Henderson DC**, Williams MA. Association of Poor Subjective Sleep Quality with Suicidal Ideation among Pregnant Peruvian Women. General Hospital Psychiatry. 2015 May 6.
7. Vincenzi B, Greene MC, Ulloa M, Parnarouskis L, Jackson JW, **Henderson DC**. Lithium or Valproate Adjunctive Therapy to Second-Generation Antipsychotics and Metabolic Variables in Patients with Schizophrenia or Schizoaffective Disorder. Journal of Psychiatry Practice, 22(3), 175–182.
8. Gelaye B, Barrios YV, Zhong Q, Rondon MB, Borba CPC, Sánchez SE, **Henderson DC**, Williams MA. Association of Poor Subjective Sleep Quality with Suicidal Ideation among Pregnant Peruvian Women. General Hospital Psychiatry. 2015 May 6.
9. **Henderson DC**, Vincenzi B, Andrea NV, Ulloa M, Copeland PM. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry. 2015 May; 2(5):452-464.
10. Gelaye B, Kajeepeta S, Zhong Q, Borba CPC, Rondon MB, Sánchez SE, **Henderson DC**, Williams MA. Childhood abuse is associated with stress-related sleep disturbance and poor sleep quality in pregnancy. Sleep Medicine. 2015; 16: 1274-1280.
11. Lavergne MR, Lethbridge L, Johnston G, **Henderson D**, D''Intino AF, McIntyre P. Examining palliative care program use and place of death in rural and urban contexts: a Canadian population-based study using linked data. Rural Remote Health. 2015 Apr-Jun; 15(2):3134.
12. Borba CPC, Gelaye B, Zayas L, Ulloa M, Lavelle J, Mollica RF, **Henderson DC**. Making strides towards better mental health care in Peru: Results from a primary care mental health training. International Journal of Clinical Psychiatry and Mental Health. 2015; 3(1): 9-19.
13. Welch LC, Litman HJ, Borba CPC, Vincenzi B, **Henderson DC**. Does a physician’s attitude towards a patient with mental illness affect clinical management of diabetes? Results from a mixed method study. Health Services Research. 2015; 50 (4): 998-1020.
14. Gelaye B, Kajeepeta S, Zhong QY, Borba CP, Rondon MB, Sánchez SE, **Henderson DC**, Williams MA. Childhood abuse is associated with stress-related sleep disturbance and poor sleep quality in pregnancy. Sleep Med. 2015 Oct; 16(10):1274-80.
15. Magidson JF, Stevenson A, Ng LC, Hock RS, Borba CP, Namey LB, Carney J, Joska JA, Kagee A, Fekadu A, Bangsberg DR, Safren SA, Fricchione GL, **Henderson DC**. Massachusetts General Hospital Global Psychiatric Clinical Research Training Program: A New Fellowship in Global Mental Health. Acad Psychiatry. 2016 Aug; 40(4):695-7
16. Ng LC, Hanlon C, Yimer G, **Henderson DC**, Fekadu A. Ethics in global health research: the need for balance. Lancet Glob Health. 2015 Sep; 3(9):e516-7.
17. Koh KA, Bharel M, **Henderson DC**. Nutrition for homeless populations: shelters and soup kitchens as opportunities for intervention. Public Health Nutr. 2016 May; 19(7):1312-4.
18. Borba CPC, Ng, LC, Stevenson A, Vesga-Lopez O, Harris BL, Parnarouskis L, Gray DA, Carney JR, Domínguez S, Wang EKS, Boxill R, Song SJ, **Henderson DC**. A mental health needs assessment of children and adolescents in post-conflict Liberia: Results from a quantitative key informant survey. International Journal of Culture and Mental Health. 2016; 9(1): 56-70.
19. Zhong QY, Gelaye B, Miller M, Fricchione GL, Cai T, Johnson PA, **Henderson DC**, Williams MA. Suicidal behavior-related hospitalizations among pregnant women in the USA, 2006-2012. Arch Womens Ment Health. 2016 Jun; 19(3):463-72.
20. Chouinard VA, Pingali SM, Chouinard G, **Henderson DC**, Mallya SG, Cypess AM, Cohen BM, Öngür D. Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders. Psychiatry Res. 2016 Mar 30; 237:304-10.
21. Pullen SJ, Petruzzi L, Lange BCL, Parnarouskis L, Dominguez S, Harris B, Quiterio N, Durham MP, Lekpeh G, Manobah B, Slopadoe SP, Diandy VC, Payne AJ, **Henderson DC**, Borba CPC. A qualitative analysis of substance use among Liberian youth: Understanding behaviors, consequences, and protective factors involving school youth and the school milieu. International Journal of Mental Health and Psychiatry. 2016; 2(1): 1-10
22. Nasser AF, **Henderson DC**, Fava M, Fudala PJ, Twumasi-Ankrah P, Kouassi A, Heidbreder C. Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study. J Clin Psychopharmacol. 2016 Apr; 36(2):130-40.
23. Vincenzi B, Greene CM, Ulloa M, Parnarouskis L, Jackson JW, **Henderson DC**. Lithium or Valproate Adjunctive Therapy to Second-generation Antipsychotics and Metabolic Variables in Patients With Schizophrenia or Schizoaffective Disorder. J Psychiatr Pract. 2016 May; 22(3):175-82.
24. Ng LC, Magidson JF, Hock RS, Joska JA, Fekadu A, Hanlon C, Galler JR, Safren SA, Borba CP, Fricchione GL, **Henderson DC**. Proposed Training Areas for Global Mental Health Researchers. Acad Psychiatry. 2016 Aug; 40(4):679-85.
25. Ng LC, Petruzzi LJ, Greene C, Mueser KT, Borba CPC, **Henderson DC**. Posttraumatic stress disorder symptoms and social and occupational functioning of people with schizophrenia. Journal of Nervous and Mental Disease. 2016 Aug; 204(8):590-8.
26. Levey EJ, Oppenheim CE, Lange BCL, Plasky NS, Harris BL, Lekpeh GG, Kekulah I, **Henderson DC**, Borba CPC. A qualitative analysis of factors impacting resilience among youth in post-conflict Liberia. Child and Adolescent Psychiatry and Mental Health. 2016 Aug; 10:26.
27. Levey, E. J., Oppenheim, C. E., Lange, B. C. L., Plasky, N. S., Harris, B. L., Lekpeh, G. G., Kekulah I., **Henderson D.C**., Borba, C. P. C. (Jan 2017). A qualitative analysis of parental loss and family separation among youth in post-conflict Liberia. Vulnerable Children and Youth Studies, 12(1), 1–16.
28. Levey EJ, Gelaye B, Bain P, Rondon MB, Borba CP, **Henderson DC**, & Williams MA. A systematic review of randomized controlled trials of interventions designed to decrease child abuse in high-risk families. Child Abuse & Neglect. 2017 Mar. 65:48-57.
29. Parnarouskis L, Stevenson A, Lange BCL, Pullen SJ, Petruzzi LJ, Dominguez S, Quiterio N, Harris B, Lekpeh GG, Manobah B, **Henderson DC**, & Borba CPC. The impact of transactional sex with teachers on public school students in Monrovia, Liberia: A brief report. Vulnerable Children and Youth Studies. 2017 March. 12(4):328-333
30. Musyimi CW, Mutiso V, Ndetei DM, **Henderson DC**, Bunders J. Mental Health Outcomes of Psychosocial Intervention Among Traditional Health Practitioner Depressed Patients in Kenya. Cult Med Psychiatry. 2017 Mar 01.
31. Denckla CA, Ndetei DM, Mutiso VN, Musyimi CW, Musau AM, Nandoya ES, Anderson KK, Milanovic S, **Henderson D**, McKenzie K. Psychometric properties of the Ndetei-Othieno-Kathuku (NOK) Scale: A mental health assessment tool for an African setting. J Child Adolesc Ment Health. 2017 May; 29(1):39-49.
32. Musyimi CW, Mutiso VN, Nayak SS, Ndetei DM, **Henderson DC**, Bunders J. Quality of life of depressed and suicidal patients seeking services from traditional and faith healers in rural Kenya. Health Qual Life Outcomes. 2017 May 08; 15(1):95.
33. Chemali Z, Borba CPC, Hock R, Johnson K, Parnakousis L, **Henderson D**, Fricchione G. Humanitarian space and wellbeing: Effectiveness of training on a psychosocial intervention for host community-refugee interaction. Medicine, Conflict and Survival. Med Confl Surviv 2017 June 33(2):141-161.
34. Welch LC, Trudeau JJ, Silverstein SM, Sand M, **Henderson DC**, Rosen RC. Initial development of a patient-reported outcome measure of experience with cognitive impairment associated with schizophrenia. Patient Relat Outcome Meas. 2017 June; 8:71-81.
35. Musyimi CW, Mutiso VN, Ndetei DM, Unanue I, Desai D, Patel SG, Musau AM, **Henderson DC**, Nandoya ES, Bunders J. Mental health treatment in Kenya: task-sharing challenges and opportunities among informal health providers. Int J Ment Health Syst. Aug 2017
36. Fan X, Song X, Zhao M, Jarskog LF, Natarajan R, Shukair N, Freudenreich O, **Henderson DC**, Goff DC. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatr Scand. 2017 Aug 29.
37. Denckla CA, Mancini AD, Consedine NS, Milanovic SM, Basu A, Seedat S, Spies G, **Henderson DC**, Bonanno GA, Koenen KC. Distinguishing postpartum and antepartum depressive trajectories in a large population-based cohort: the impact of exposure to adversity and offspring gender. Psychol Med. 2017 Sep 11; 1-11.
38. Hock RS, Bryce CP, Waber DP, McCuskee S, Fitzmaurice GM, **Henderson DC**, Galler JR. Relationship between infant malnutrition and childhood maltreatment in a Barbados lifespan cohort. Vulnerable Child Youth Stud. 2017 Sep 6
39. Levey EJ, Gelaye B, Koenen K, Zhong QY, Basu A, Rondon MB, Sanchez S, **Henderson DC**, Williams MA. Trauma exposure and post-traumatic stress disorder in a cohort of pregnant Peruvian women. Arch Womens Ment Health. 2017 Sep 13.
40. Musyimi CW, Mutiso V, Ndetei DM, **Henderson DC**, Bunders J. Mental Health Outcomes of Psychosocial Intervention Among Traditional Health Practitioner Depressed Patients in Kenya. Cult Med Psychiatry. 2017 Sep 41(3):453-465
41. Mehralizade A, Schor S, Coleman CM, Oppenheim CE, Denckla CA, Borba CP, **Henderson DC**, Wolff J, Crane S, Nettles-Gomez P, Pal A, Milanovic S. Mobile Health Apps in OB-GYN-Embedded Psychiatric Care: Commentary. JMIR Mhealth Uhealth. 2017 Oct 6
42. Nemani KL, Greene MC, Ulloa M, Vincenzi B, Copeland PM, Al-Khadari S, **Henderson DC.** Clozapine, Diabetes Mellitus, Cardiovascular Risk and Mortality: Results of a 21-year Naturalistic Study in Patients with Schizophrenia and Schizoaffective Disorder. Clin Schizophr Relat Psychoses. 2017 Nov 22.
43. Fan X, Song X, Zhao M, Jarskog LF, Natarajan R, Shukair N, Freudenreich O, **Henderson DC**, Goff DC. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatr Scand. 2017 Nov; 136(5):465-472
44. Gelaye B, Zhong QY, Basu A, Levey EJ, Rondon MB, Sanchez S, Koenen KC, **Henderson DC**, Williams MA. Trauma and traumatic stress in a sample of pregnant women. Psychiatry Res. 2017 Nov 257:506-513
45. Denckla CA, Consedine NS, Spies G, Cherner M, **Henderson DC**, Koenen KC, Seedat S. Associations between neurocognitive functioning and social and occupational resilience among South African women exposed to childhood trauma. Eur J Psychotraumatol. 2017 Nov 2
46. Parnarouskis L, Stevenson A, Lange BCL, Pullen SJ, Petruzzi LJ, Dominguez S, Quiterio N, Harris B, Lekpeh GG, Manobah B, **Henderson DC**, Borba CPC. The impact of transactional sex with teachers on public school students in Monrovia, Liberia - a brief report. Vulnerable Child Youth Stud. 2017;12
47. Mulderig A, Beaucage G, Vogtt K, Jiang H, Jin Y, Clapp L, **Henderson DC**. Structural Emergence in Particle Dispersions. Langmuir. 2017 Dec 12
48. Pino EC, Damus K, Jack B, **Henderson DC**, Milanovic S, Kalesan B. Adolescent socioeconomic status and depressive symptoms in later life: Evidence from structural equation models. J Affect Disord. 2018 Jan 01; 225:702-708
49. Jackson JW, Fulchino L, Rogers J, Mogun H, Polinski J, **Henderson DC**, Schneeweiss S, Fischer MA. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients". Pharmacoepidemiol Drug Saf. 2018 Jan; 27(1):95-104.
50. Roffman JL, Petruzzi LJ, Tanner AS, Brown HE, Eryilmaz H, Ho NF, Giegold M, Silverstein NJ, Bottiglieri T, Manoach DS, Smoller JW, **Henderson DC**, Goff DC. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial. Mol Psychiatry. 2018 Feb (2):316-322
51. Petruzzi LJ, Pullen SJ, Lange BCL, Parnarouskis L, Dominguez S, Harris B, Quiterio N, Lekpeh G, Manobah B, **Henderson DC**, Borba CPC. Contributing Risk Factors for Substance Use Amoung Youth in Postconflict Liberia. Qual Health Res. 2018 Mar 01.
52. Chouinard VA, **Henderson DC**, Dalla Man C, Valeri L, Gray BE, Ryan KP, Cypess AM, Cobelli C, Cohen BM, Öngür D. Impaired insulin signaling in unaffected siblings and patients with first-episode psychosis. Mol Psychiatry. 2018 Mar 09.
53. Levey EJ, Gelaye B, Koenen K, Zhong QY, Basu A, Rondon MB, Sanchez S, **Henderson DC**, Williams MA. Trauma exposure and post-traumatic stress disorder in a cohort of pregnant Peruvian women. Arch Womens Mental Health. 2018 April
54. Denckla CA, Mancini AD, Consedine NS, Milanovic SM, Basu A, Seedat S, Spies G, **Henderson DC**, Bonanno GA, Koenen KC. Distinguishing postpartum and antepartum depressive trajectories in a large population-based cohort: the impact of exposure to adversity and offspring gender. Psychol Med. 2018 May
55. Levey EJ, Laird LD, Becker AE, Harris BL, Lekpeh GG, Oppenheim CE, **Henderson DC**, Borba CPC. Narratives of Agency and Capability from Two Adolescent Girls in Post-conflict Liberia. Cult Med Psychiatry. 2018 Aug 03.
56. Pino EC, Zuo Y, Borba CP, **Henderson DC,** Kalesan B. Clinical depression and anxiety among ST-elevation myocardial infarction hospitalizations: Results from Nationwide Inpatient Sample 2004-2013. Psychiatry Res. 2018 Aug; 266:291-300.
57. Petruzzi LJ, Pullen SJ, Lange BCL, Parnarouskis L, Dominguez S, Harris B, Quiterio N, Lekpeh G, Manobah B, **Henderson DC**, Borba CPC. Contributing Risk Factors for Substance Use Among Youth in Postconflict Liberia. Qual Health Res. 2018 Oct;28 (12):1827-1838
58. Pino EC, Zuo Y, Schor SH, Zatwarnicki S, **Henderson DC**, Borba CP, Milanovic SM, Kalesan B. Temporal trends of co-diagnosis of depression and/or anxiety among female maternal and non-maternal hospitalizations: Results from Nationwide Inpatient Sample 2004-2013. Psychiatry Res. 2018 Dec 15; 272:42-5.
59. Halim N, Beard J, Mesic A, Patel A, **Henderson DC**, Hibberd P. Intimate partner violence during pregnancy and perinatal mental disorders in low and lower middle income countries: A systematic review of literature, 1990-2017. Clin Psychol Rev. 2018 Dec.66:117-135
60. Pino EC, Zuo Y, Borba CP, **Henderson DC**, Kalesan B. Reply to psychiatric disorders' paradoxical protective effect on cardiovascular procedures and mortality. Psychiatry Res. 2018 Dec;270:1181-1183
61. Levey EJ, Laird LD, Becker AE, Harris BL, Lekpeh GG, Oppenheim CE, **Henderson DC**, Borba CPC. Narratives of Agency and Capability from Two Adolescent Girls in Post-conflict Liberia. Cult Med Psychiatry. 2018 Dec;42(4):947-979
62. Herman AR, Pullen SJ, Lange BCL, Christian-Brathwaite N, Ulloa M, Kempeh M, Karnga D, Johnson D, Harris B, **Henderson DC**, Borba CPC. Closing the Mental Health Treatment Gap through the Collaboration of Traditional and Western Medicine in Liberia. Int J Cult Ment Health. 2018; 11(4):693-704.View Related Profiles. PMID: [31467591](https://www.ncbi.nlm.nih.gov/pubmed/31467591).
63. Hailemariam M, Ghebrehiwet S, Baul T, Restivo JL, Shibre T, **Henderson DC**, Girma E, Fekadu A, Teferra S, Hanlon C, Johnson JE, Borba CPC. "He can send her to her parents": The interaction between marriageability, gender and serious mental illness in rural Ethiopia. BMC Psychiatry. 2019 Oct 26; 19(1):315.View Related Profiles. PMID: [31655561](https://www.ncbi.nlm.nih.gov/pubmed/31655561).
64. Ghebrehiwet S, Baul T, Restivo JL, Kelkile TS, Stevenson A, Gelaye B, Fekadu A, Hailemariam M, Girma E, Teferra S, Canelos V, **Henderson DC**, Borba CPC. Gender-specific experiences of serious mental illness in rural Ethiopia: A qualitative study. Glob Public Health. 2019 Oct 20; 1-15.View Related Profiles. PMID: [31630624](https://www.ncbi.nlm.nih.gov/pubmed/31630624).
65. Irwin KE, Steffens EB, Yoon Y, Flores EJ, Knight HP, Pirl WF, Freudenreich O, **Henderson DC**, Park ER. Lung Cancer Screening Eligibility, Risk Perceptions, and Clinician Delivery of Tobacco Cessation Among Patients With Schizophrenia. Psychiatr Serv. 2019 Oct 01; 70(10):927-934. PMID: [31357921](https://www.ncbi.nlm.nih.gov/pubmed/31357921).
66. Rosato AJ, Chen X, Tanaka Y, Farrer LA, Kranzler HR, Nunez YZ, **Henderson DC**, Gelernter J, Zhang H. Salivary microRNAs identified by small RNA sequencing and machine learning as potential biomarkers of alcohol dependence. Epigenomics. 2019 May; 11(7):739-749.View Related Profiles. PMID: [31140863](https://www.ncbi.nlm.nih.gov/pubmed/31140863).
67. Montalvo C, Stankiewicz B, Brochier A, **Henderson DC**, Borba CPC. Long-Term Retention in an Outpatient Behavioral Health Clinic With Buprenorphine. Am J Addict. 2019 Sep; 28(5):339-346.View Related Profiles. PMID: [31066985](https://www.ncbi.nlm.nih.gov/pubmed/31066985).
68. Denckla CA, Spies G, Heaton R, Vasterling J, Franklin D, Korte KJ, Colgan C, **Henderson DC**, Koenen KC, Seedat S. Generalizability of demographically corrected Zambian neuropsychological norms to South African women. Clin Neuropsychol. 2019 Apr 05; 1-18.View Related Profiles. PMID: [30950749](https://www.ncbi.nlm.nih.gov/pubmed/30950749).
69. Fan X, Copeland P, Nawras S, Harrington A, Freudenreich O, Goff DC, **Henderson DC**. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. Psychopharmacology (Berl). 2019 Jun; 236(6):1949-1957. PMID: [30747254](https://www.ncbi.nlm.nih.gov/pubmed/30747254).
70. Pino EC, Zuo Y, Schor SH, Zatwarnicki S, **Henderson DC**, Borba CP, Milanovic SM, Kalesan B. [Temporal trends of co-diagnosis of depression and/or anxiety among female maternal and non-maternal hospitalizations: Results from Nationwide Inpatient Sample 2004-2013.](https://www.ncbi.nlm.nih.gov/pubmed/30579180) Psychiatry Res. 2019 Feb;272:42-50. doi: 10.1016/j.psychres.2018.12.077. Epub 2018 Dec 15. PMID: 30579180
71. Denckla CA, Ongeri L, Ouma L, Singa B, Maingi C, Bosire R, Otieno P, Omolo D, **Henderson DC**, Chibnik LB, Koenen KC, Manduku V. Prevalence of parental bereavement among female sex workers (FSW) in Kibra, Kenya. J Loss Trauma. 2019; 24(2):129-142.View Related Profiles. PMID: [31598099](https://www.ncbi.nlm.nih.gov/pubmed/31598099).
72. Oppenheim CE, Axelrod K, Menyongai J, Chukwuezi B, Tam A, **Henderson DC**, Borba CPC. The HEAAL Project: Applying Community-Based Participatory Research (CBPR) Methodology in a Health and Mental Health Needs Assessment With an African Immigrant and Refugee Faith Community in Lowell, Massachusetts. J Public Health Manag Pract. 2019 Jan/Feb; 25(1):E1-E6. PMID: [30507809](https://www.ncbi.nlm.nih.gov/pubmed/30507809).
73. Ogundare T, Adebowale TO, Borba CPC, **Henderson DC**. [Correlates of depression and quality of life among patients with epilepsy in Nigeria.](https://www.ncbi.nlm.nih.gov/pubmed/32361406) Epilepsy Res. 2020 Apr 25;164:106344. doi: 10.1016/j.eplepsyres.2020.106344. [Epub ahead of print] PMID:32361406
74. Brown HE, Feinstein S, **Henderson DC**. [Working With Patients With Impaired Insight.](https://www.ncbi.nlm.nih.gov/pubmed/32347904) JAMA Psychiatry. 2020 Apr 29. doi: 10.1001/jamapsychiatry.2020.0767. [Epub ahead of print] No abstract available. PMID: 32347904
75. Vallath S, Ravikanth L, Regeer B, Borba PC, **Henderson DC**, Scholte WF. [Traumatic loss and psychosis - reconceptualising the role of trauma in psychosis.](https://www.ncbi.nlm.nih.gov/pubmed/32341762) Eur J Psychotraumatol. 2020 Mar 26;11(1):1725322. doi: 10.1080/20008198.2020.1725322. eCollection 2020. PMID: 32341762
76. Lin Y, Kranzler HR, Farrer LA, Xu H, **Henderson DC**, Zhang H. [An analysis of the effect of mu-opioid receptor gene (OPRM1) promoter region DNA methylation on the response of naltrexone treatment of alcohol dependence.](https://www.ncbi.nlm.nih.gov/pubmed/32029903) Pharmacogenomics J. 2020 Feb 7. doi: 10.1038/s41397-020-0158-1. [Epub ahead of print] PMID: 32029903
77. Ghebrehiwet S, Baul T, Restivo JL, Kelkile TS, Stevenson A, Gelaye B, Fekadu A, Hailemariam M, Girma E, Teferra S, Canelos V,**Henderson DC**, Borba CPC. [Gender-specific experiences of serious mental illness in rural Ethiopia: A qualitative study.](https://pubmed.ncbi.nlm.nih.gov/31630624/) Glob Public Health. 2020 Feb;15(2):185-199. doi: 10.1080/17441692.2019.1680723. Epub 2019 Oct 20.PMID: 31630624
78. Carroll HA, Hook K, Perez OFR, Denckla C, Vince CC, Ghebrehiwet S, Ando K, Touma M, Borba CPC, Fricchione GL,**Henderson DC.** [Establishing reliability and validity for mental health screening instruments in resource-constrained settings: Systematic review of the PHQ-9 and key recommendations.](https://pubmed.ncbi.nlm.nih.gov/32593853/) Psychiatry Res. 2020 Sep;291:113236. doi:10.1016/j.psychres.2020.113236. Epub 2020 Jun 18.PMID: 32593853
79. Lin H, Wang F, Rosato AJ, Farrer LA,**Henderson DC**, Zhang H. [Prefrontal cortex eQTLs/mQTLs enriched in genetic variants associated with alcohol use disorder and other diseases.](https://pubmed.ncbi.nlm.nih.gov/32496132/) Epigenomics. 2020 May;12(9):789-800. doi: 10.2217/epi-2019-0270. Epub 2020 Jun 4.PMID: 32496132
80. Mylonas D, Baran B, Demanuele C, Cox R, Vuper TC, Seicol BJ, Fowler RA, Correll D, Parr E, Callahan CE, Morgan A, Henderson D, Vangel M, Stickgold R, Manoach DS. The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized clinical trial. Neuropsychopharmacology. 2020 Sep 12. PMID: [32919407](https://www.ncbi.nlm.nih.gov/pubmed/32919407)

**Reviews:**

1. **Henderson** **DC**: Treatment-resistant schizophrenia. Practical Reviews in Psychiatry, 1995; 19(9):1-2.
2. **Henderson DC**, Goff DC: An approach to treatment-resistant schizophrenia. American Society of Clinical Psychopharmacology Progress Notes 1995;6:2-4.
3. **Henderson DC**: The efficacy of olanzapine for treating the behavioral and psychological problems of Alzheimer’s patients. Current Practice of Medicine 1999; 2:149-151.
4. Goldstein L, **Henderson DC**: Atypical antipsychotic agents and diabetes mellitus. Primary Psychiatry 2000; 7:65-68.
5. **Henderson DC**. Atypical antipsychotic agents-induced diabetes mellitus: How

strong is the evidence? CNS Drugs 2002; 16:77-89.

1. **Henderson DC**. Atypical antipsychotic agents- diabetes and Bergman’s minimal model analysis. Japanese Journal of Clinical Psychopharmacology 2002; 5:927-938
2. [Tamminga CA](http://www.ncbi.nlm.nih.gov/pubmed?term=Tamminga%20CA%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Nemeroff CB](http://www.ncbi.nlm.nih.gov/pubmed?term=Nemeroff%20CB%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Blakely RD](http://www.ncbi.nlm.nih.gov/pubmed?term=Blakely%20RD%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Brady L](http://www.ncbi.nlm.nih.gov/pubmed?term=Brady%20L%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Carter CS](http://www.ncbi.nlm.nih.gov/pubmed?term=Carter%20CS%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Davis KL](http://www.ncbi.nlm.nih.gov/pubmed?term=Davis%20KL%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Dingledine R](http://www.ncbi.nlm.nih.gov/pubmed?term=Dingledine%20R%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Gorman JM](http://www.ncbi.nlm.nih.gov/pubmed?term=Gorman%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Grigoriadis DE](http://www.ncbi.nlm.nih.gov/pubmed?term=Grigoriadis%20DE%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [**Henderson DC**](http://www.ncbi.nlm.nih.gov/pubmed?term=Henderson%20DC%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [B Innis RB](http://www.ncbi.nlm.nih.gov/pubmed?term=B%20Innis%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Killen J](http://www.ncbi.nlm.nih.gov/pubmed?term=Killen%20J%5BAuthor%5D&cauthor=true&cauthor_uid=12361670),[Laughren TP](http://www.ncbi.nlm.nih.gov/pubmed?term=Laughren%20TP%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [McDonald WM](http://www.ncbi.nlm.nih.gov/pubmed?term=McDonald%20WM%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [M Murphy GM Jr](http://www.ncbi.nlm.nih.gov/pubmed?term=M%20Murphy%20GM%20Jr%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Paul SM](http://www.ncbi.nlm.nih.gov/pubmed?term=Paul%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Rudorfer MV](http://www.ncbi.nlm.nih.gov/pubmed?term=Rudorfer%20MV%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Sausville E](http://www.ncbi.nlm.nih.gov/pubmed?term=Sausville%20E%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Schatzberg AF](http://www.ncbi.nlm.nih.gov/pubmed?term=Schatzberg%20AF%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Scolnick EM](http://www.ncbi.nlm.nih.gov/pubmed?term=Scolnick%20EM%5BAuthor%5D&cauthor=true&cauthor_uid=12361670), [Suppes T](http://www.ncbi.nlm.nih.gov/pubmed?term=Suppes%20T%5BAuthor%5D&cauthor=true&cauthor_uid=12361670). Developing novel treatments for mood disorders: accelerating discovery. Biological Psychiatry. 2002; 2 (6): 589-609.
3. **Henderson DC**, Ettinger ER. Schizophrenia and diabetes. Int Rev Neurobiol 2002;51:481-501.
4. Goff DC, Cather C, Evins AE, **Henderson DC**, Freudenreich O, Copeland P, Birer M, Duckworth K, Sacks F: Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psych 2005; 66:183-194.
5. Fan X, Goff DC, **Henderson DC**. Inflammation and schizophrenia. Expert Rev Neurother. 2007 Jul; 7(7):789-796.
6. **Henderson DC**. Managing weight gain and metabolic issues in patients treated with atypical antipsychotics. J Clin Psychiatry. 2008;69(2):e04.
7. **Henderson DC**, Doraiswamy PM: Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry 2008; 69 Suppl 1:32-44.
8. **Henderson DC**. [Antipsychotic treatment associated with higher risk of hyperglycaemia in older persons with diabetes.](http://www.ncbi.nlm.nih.gov/pubmed/21856623) Evid Based Ment Health. 2010 May;13(2):60.
9. Ameresekere, M, **Henderson, DC**. Post-conflict mental health in South Sudan: overview of common psychiatric disorders, part 1: depression and post-traumatic stress disorder. South Sudan Med J. Feb. 2012; 5(1): 4-8.
10. Ameresekere, M, **Henderson, DC**. Post-conflict mental health in South Sudan: Overview of common psychiatric disorders, part 2: anxiety and substance abuse. South Sudan Med J. 2012 5(2) 32-36.
11. Thakurathi, N., **Henderson, DC**. Atypical antipsychotics are associated with incident diabetes in older adults without schizophrenia or bipolar disorder. Evid Based Ment Health. 2012 Aug;15(3):61.
12. Sharma B, **Henderson DC**: Sibutramine: Current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother. 2008 Aug; 9(12):2161-2173.
13. Fricchione G, Borba CP, Alem A, Shibre T, Carney JR, **Henderson DC**. Capacity building in global mental health: professional training. Harv Rev Psychiatry. 2012 Jan-Feb;20(1) 47-57.
14. Freudenreich O, **Henderson DC**, Sanders KM, Goff DC. [Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation.](http://www.ncbi.nlm.nih.gov/pubmed/23338869) Acad Psychiatry. 2013 Jan 1;37(1):27-30.
15. Thakurathi N, Vincenzi B, **Henderson DC**. [Assessing the prospect of donepezil in improving cognitive impairment in patients with schizophrenia.](http://www.ncbi.nlm.nih.gov/pubmed/23215841) Expert Opin Investig Drugs. 2013 Feb;22(2):259-265.
16. Irwin KE, **Henderson DC**, Knight HP, Pirl WF. [Cancer care for individuals with schizophrenia.](http://phstwlp1.partners.org:2111/pubmed/24151022) Cancer. 2013 Oct 21. doi: 10.1002/cncr.28431. PMID: 24151022

**Clinical Communications:**

1. Borba CP, **Henderson DC**. Citalopram and clozapine: Potential drug interaction. Journal of Clinical Psychiatry. 2000; 61(4): 301-302.
2. **Henderson DC**, Borba CP. Trimethoprim-sulfamethoxazole and clozapine. Psychiatric Services. 2001; 52(1):111-112.
3. Lafayette JM, Pirl WF, **Henderson DC**. Low-dose clozapine associated with diabetic ketoacidosis. Psychosomatics. 2003; 44:249-2
4. **Henderson DC**, Koul P, Namey L, Daley TB, Nguyen DD, Louie PM, Goff DC: Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. 2005; Ann Clin Psych 17:95-97

[**Non-peer reviewed scientific or medical publications/materials in print or other media**](http://cv.hms.harvard.edu/index.php?page=no_peerreview)

|  |
| --- |
| **Proceedings of meetings or other non-peer reviewed research publications****Reviews:**1. **Henderson DC:** Risperidone added to clozapine. Clinical Psychiatric News, 1997.
2. **Henderson DC**. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001; 62 supplement 23:39-44
3. **Henderson DC**. Clinical experience with insulin resistance, diabetic ketoacidosis and type II diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiatry 2001; 62[suppl 27]:10-14.
4. Casey DE, Haupt DW, Newcomer JW, **Henderson DC**, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH: Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia: J Clin Psychiatry 2004; 65 Suppl 7: 4-18.
5. **Henderson, DC**. The Art of Practice: What should physicians know about the metabolic effects of second-generation antipsychotic medications? Massachusetts General Hospital Curbside Consultant 2005; 3 (6) 3-4.
6. **Henderson DC**. Metabolic differences of antipsychotics among the races. CNS Spectrum 2005; 10 suppl 2:13-20.
7. **Henderson DC**: Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005; 66 Suppl 6:11-20.
8. **Henderson DC**. [Considerations for inpatient versus outpatient treatment with antipsychotics.](http://www.ncbi.nlm.nih.gov/pubmed/18389922) CNS Spectr. 2007 Dec; 12(12 Suppl 21):3-5.
9. **Henderson, DC**. Weight gain with atypical antipsychotics: evidence and insights. J Clin Psychiatry 2007; 68 Suppl 12:18-26.

**Proceedings of Meetings:**1. **Henderson DC**: The use of clozapine in minority schizophrenics in Massachusetts. In: Proceedings of the First Annual Symposium for Mental Health Professionals of Color, Boston, MA, 1993.
2. **Henderson DC**: Psychopharmacologic Issues in the Treatment of African Americans. In: Proceedings of the Second Annual Symposium for Mental Health Professionals of Color, Worcester, MA, 1995.
3. **Henderson DC**: Treatment resistant schizophrenia in African-Americans. In: proceedings of The National Medical Association Scientific Assembly, Chicago IL, 1996.
4. **Henderson DC**: Herbal medicines and drug interactions. In: proceedings of The National Medical Association Scientific Assembly, Honolulu, Hawaii, 1997.
5. **Henderson DC**: Clinical Issues in Ethno psychopharmacology. In: Proceedings of the Multicultural Mental Health Research in the Twenty-first Century. Boston, MA 1997.

**Book Chapters:**1. Goff DC, **Henderson DC**: Treatment resistant schizophrenia. In Pollack MH, Otto MW, Rosenbaum JF (eds). Challenges in Clinical Practice Pharmacologic and Psychosocial Strategies. New York: Guilford Press Co, 1996:311-328.
2. Goff DC, **Henderson DC**, Manschreck TC: Psychotic patients. In Cassem NH, Stern TA, Rosenbaum JF, Jellinek MS (eds). Massachusetts General Hospital Handbook of General Hospital Psychiatry, Fourth Edition. St. Louis: Mosby -Year Book, INC., 1997:149-171.
3. **Henderson DC**: Treatment of African Americans with schizophrenia. In Herrera J, Lawson W, Sramek J, (eds). Cross-Cultural Psychiatry. New York City: John Wiley & Sons, 1999:165-182.
4. **Henderson DC,** Goff DC: Antipsychotic agents. In Stern TA, Herman JB (eds). The Psychiatry Update and Board Preparation. New York City: McGraw-Hill 2000: 345-351.
5. **Henderson DC**, Goff DC: Psychosis and schizophrenia. In Stern TA, Herman JB (eds). Psychiatry Update and Board Preparation. New York City McGraw-Hill 2000: 97-102.
6. **Henderson DC**, Mollica RF. Developing effective mental health policies and services for traumatized refugee patients. In Koslow DR, Salett EP (eds.). Crossing Cultures in Mental Health 2nd Edition. Washington, DC. National Multi-Cultural Institute. 2003
7. **Henderson DC**, Ettinger, EP. Glucose intolerance and diabetes in patients with schizophrenia. In Meyer JM and Nasrallah HA, (eds). Medical Illness and Schizophrenia. Washington DC: American Psychiatric Publishing, INC., 2003; 99-114.
8. **Henderson DC**, Kunkel L, Goff DC: Antipsychotic agents. In Stern TA, Herman JB (eds). The Psychiatry Update and Board Preparation. Second Edition, NY. McGraw-Hill. 2003; 335-341.
9. **Henderson DC**, Kunkel L, Goff DC: Psychosis and schizophrenia. In Stern TA, Herman JB (eds). Psychiatry Update and Board Preparation. Second Edition, NY, McGraw-Hill. 2003; 97-102.
10. **Henderson DC**, Nguyen DD: Culture and psychiatry. In Stern TA, Herman JB (eds). Massachusetts General Hospital Psychiatry Update and Board Preparation. 2nd Edition, New York City, McGraw-Hill. 2004; 551-555.
11. **Henderson DC**, Nguyen DD, et al.: Culture and psychiatry. In Stern TA, Fricchione GL, Cassem NH, Jellinek MS, Rosenbaum JR (eds). Massachusetts General Hospital Handbook of General Psychiatry. Philadelphia PA, Mosby and Elsevier, Inc, 2004; 737-747.
12. **Henderson DC**, Nguyen DD, Vuky C: Importance of culture. In Stern TA (ed). The 10-Minute Guide to Psychiatric Diagnosis and Treatment. Professional Publishing Group. New York City: Professional Publishing Group, 2005; 447-462.
13. Borba CPC, **Henderson DC**. Depression and Psychiatric Disorders. In Thompson LU, Ward WE, (eds). Optimizing Women’s Health through Nutrition. New York City, Taylor and Francis CRC Press. 2008; 383-394.
14. Goff DC, Freudenreich O, **Henderson DC**. Antipsychotic Drugs. In  Stern TA, [Rosenbaum](http://www.kobobooks.com/search/search.html?q=%22Jerrold+F.+Rosenbaum%22&t=none&f=author&p=1&s=none&g=both) JF,  [Biederman](http://www.kobobooks.com/search/search.html?q=%22Joseph+Biederman%22&t=none&f=author&p=1&s=none&g=both) J, [Fava](http://www.kobobooks.com/search/search.html?q=%22Maurizio+Fava%22&t=none&f=author&p=1&s=none&g=both) M, [Rauch](http://www.kobobooks.com/search/search.html?q=%22Scott+L.+Rauch%22&t=none&f=author&p=1&s=none&g=both) SL (eds). Massachusetts General Hospital Comprehensive Clinical Psychiatry. Philadelphia, Mosby, Inc and Elsevier, Inc. 2008; 577-594.
15. **Henderson DC**, Yeung A, Fan X, Fricchione GL. Culture and Psychiatry In  Stern TA, [Rosenbaum](http://www.kobobooks.com/search/search.html?q=%22Jerrold+F.+Rosenbaum%22&t=none&f=author&p=1&s=none&g=both) JF, [Biederman](http://www.kobobooks.com/search/search.html?q=%22Joseph+Biederman%22&t=none&f=author&p=1&s=none&g=both) J, [Fava](http://www.kobobooks.com/search/search.html?q=%22Maurizio+Fava%22&t=none&f=author&p=1&s=none&g=both) M, [Rauch](http://www.kobobooks.com/search/search.html?q=%22Scott+L.+Rauch%22&t=none&f=author&p=1&s=none&g=both) SL (eds). Massachusetts General Hospital Comprehensive Clinical Psychiatry. Philadelphia, Mosby, Inc and Elsevier, Inc. 2008; 907-916.
16. Mollica RF, Hovelson DH, **Henderson DC**, Fricchione GL. International Psychiatry in the Twenty-first Century. In  Stern TA, [Rosenbaum](http://www.kobobooks.com/search/search.html?q=%22Jerrold+F.+Rosenbaum%22&t=none&f=author&p=1&s=none&g=both) JF, [Biederman](http://www.kobobooks.com/search/search.html?q=%22Joseph+Biederman%22&t=none&f=author&p=1&s=none&g=both) J, [Fava](http://www.kobobooks.com/search/search.html?q=%22Maurizio+Fava%22&t=none&f=author&p=1&s=none&g=both) M, [Rauch](http://www.kobobooks.com/search/search.html?q=%22Scott+L.+Rauch%22&t=none&f=author&p=1&s=none&g=both) SL (eds). Massachusetts General Hospital Comprehensive Clinical Psychiatry, Mosby, Inc and Elsevier, INC. 2008.1243-1254.
17. Borba CPC, **Henderson DC**. Depression and psychiatric disorders. In Thompson LU, Ward WE (eds.). Optimizing women’s health through nutrition. Boca Raton, Florida, CRC Press Taylor and Francis Group. 2008: 383-394.
18. **Henderson DC** and Miley K: Glucose Intolerance and Diabetes in Schizophrenia. In Meyer JM, Nasrallah HA (eds). Medical Illness and Schizophrenia. 2nd Edition. Arlington, VA; American Psychiatric Press, Inc. 2008.91-116.
19. **Henderson DC**: Pharmacotherapy in African Americans. In Hampton R, Gullotta TP(eds). *The Handbook of African American Health.* New York, NY, The Guilford Press. 2009; 140-153.
20. **Henderson DC**, Shin L. Obesity and Metabolic Dysfunction in the Child with a Major Behavioral Disorder: Atypical Antipsychotics. In Freemark MS (ed). *Pediatric Obesity: Etiology, Pathogenesis, and Treatment* New York, NY: Humana Press. 2010*;* 369-376.
21. **Henderson DC**, Thakurathi N. Psychosis and Schizophrenia. In Stern TA, Herman JB, Gorindo TL (eds.) *Massachusetts General Hospital Psychiatry Update and Board Preparation, 3rd edition.* Boston, MA: MGH Psychiatry Academy Publishing. 2012; 113-117.
22. **Henderson DC**, Thakurathi N. Antipsychotic Drugs. In Stern TA, Herman JB, Gorindo TL (eds.) *Massachusetts General Hospital Psychiatry Update and Board Preparation, 3rd edition.* Boston, MA: MGH Psychiatry Academy Publishing. 2012; 359-365.
23. Donovan AL, Powell AD, **Henderson DC.** Chronic Mental Illness. In Stern TA, Herman JB, Gorindo TL (eds.) *Massachusetts General Hospital Psychiatry Update and Board Preparation, 3rd edition.* Boston, MA: MGH Psychiatry Academy Publishing. 2012; 535-539.
24. Trinh N, **Henderson DC**. Culture and Psychiatry. In Stern TA, Herman JB, Gorindo TL (eds.) *Massachusetts General Hospital Psychiatry Update and Board Preparation, 3rd edition.* Boston, MA: MGH Psychiatry Academy Publishing. 2012; 553-557.
25. **Henderson DC**, Sarvet A, Carney J. Pharmacology and Primary Prevention. In Encyclopedia of Primary Prevention and Health Promotion, 2nd Ed. Editors: Bloom M, Gullotta TP. New York, Springer Science and Business Media. In Press.
26. **Henderson DC**, Vincenzi B. Ethnopsychopharmacology. In Lim R (ed). Clinical Manual of Cultural Psychiatry, 2nd Edition. Clinical Manual of Cultural Psychiatry, 2nd Edition. Arlington, VA: American Psychiatric Publishing. 2014
27. **Henderson DC**, **Vincenzi B**, Yeung AS, Fricchione G. Culture and Psychiatry. In Stern, AT (Ed), Massachusetts General Hospital Comprehensive Clinical Psychiatry. Second Edition. Mosby, Inc and Elsevier. 2015.
28. Mollica RF, Borba CPC, Katon JM, Oppenheim CE, Fricchione GL, **Henderson DC**. Global Mental Health in the Twenty-first Century. In Stern TA, Fava M, Wilens TE, Rosenbaum J (Eds.). Massachusetts General Hospital Comprehensive Clinical Psychiatry, 2nd Edition. London, Elsevier Inc. 2016: 990-999.

**Letters to the editor:**1. **Henderson DC**. Aripiprazole in chronic schizophrenia: experiences in daily practice-Reply. Acta Psychiatrica Scandinavica 2006; 114 (4): 294 294.
2. **Henderson DC**. What do we know about insulin resistance and glucose metabolism in patients with schizophrenia treated with antipsychotics? Reply. Journal of Clinical Psychiatry. 2007; 68 (5): 801-802.
3. Evins AE, Cather C, Deskersbach T, **Henderson DC**. Smoking cessation in schizophrenia-reply to comments by Dr. Babbar. Journal of Clinical Psychopharmacology. 2007; 27 (2): 240-240.
 |

[**Professional educational materials or reports, in print or other media**](http://cv.hms.harvard.edu/index.php?page=print)

|  |
| --- |
| 1. “Back from madness” Ken Rosenberg MD, producer; an HBO film about mental illness. 1996 Filmed interviewing a patient with schizophrenia.
2. “Trauma and Central Africa” Voice of America 1996-97 Developed content for weekly radio program on trauma and mental health.
3. **Henderson DC**, Van der Velde P, Mollica RF, Lavelle J: The crisis in Rwanda: mental health in the service of justice and healing. Harvard Program in Refugee Trauma, Harvard School of Public Health, 1996
4. Rapid Public Health Assessment of Disaster Mental Health Needs9 Days Post Hurricane Katrina, Operation DR # 865, American Red Cross, Washington DC
5. The Republic of Liberia, National Mental Health Policy, Ministry of Health and Social Welfare 2009, Monrovia Liberia
 |

**Short Communications:**

1. Magidson JF, Stevenson A, Ng LC, Hock RS, Borba CPC, Namey LB, Carney J, Joska JA, Kagee A, Fekadu A, Bangsberg DR, Safren SA, Fricchione GL, **Henderson DC**. Massachusetts General Hospital (MGH) Global Psychiatric Clinical Research Training Program: A New Fellowship in Global Mental Health. Academic Psychiatry. In press.

**Published Study Protocols:**

1. Fekadu A, Mesfin M, Medhin G, Alem A, Teferra S, Gebre-Eyesus T, Seboxa T, Assefa A, Hussein J, Lemma MT, Borba CPC, **Henderson DC**, Hanlon C, Shibre T. Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial. Trials: 2013; 14: Article #406.
2. Borba CPC, Fekadu A, Teferra S, Bekele D, Shibre T, Oppenheim CE, Schoenfeld DA, **Henderson DC**. A placebo-controlled trial of folate with B12 in patients with schizophrenia with residual symptoms in Ethiopia using a sequential parallel comparison design. British Journal of Medicine and Medical Research. 2014; 4(23): 4090-4104.

|  |  |
| --- | --- |
| **Selected Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings:** |  |
|  |  |
| 1. Borba CPC, Fan X, Oppenheim CE, Cleary SM, Namey Briggs LB, **Henderson DC**. Baseline prolactin levels in patients with schizophrenia taking paliperidone ER, paliperidone palmitate, or risperidone consta therapy. Poster Presentation: Institute on Psychiatric Services 63rd Annual Meeting, San Francisco, CA 2011
2. **Henderson DC, Welch L, Borba CPC, Does a Physician’s Attitude towards a Patient with Mental Illness Affect the Clinical Management of Diabetes? Results from a Mixed Method Study.** Academy Health’s 2013 Annual Research Meeting (ARM), Baltimore, MD
3. **Myers J, Henderson DC,** Kianifard F, Meng X, Winseck A. Does Ethnicity Affect Clinical Outcomes and Tolerability in Patients With Schizophrenia Who Switch to Iloperidone? APA 2013 San Francisco
4. **Henderson DC**, Welch LC, Litman HJ, Borba CPC, McKinlay JB. **Does a Physician’s Attitude towards a Patient with Mental Illness Affect the Clinical Management of Diabetes? Results from a Mixed Method Study. Poster Presentation:** AcademyHealth’s Annual Research Meeting, Baltimore, MD 2013
5. Vincenzi B, Welch LC, Pober D, Trachtenberg F, Borba CPC, **Henderson DC**. Physician attitudes about mental illness, the role of context, and clinical management of diabetes in the presence of a mental health comorbidity: Results from a factorial experiment. Poster Presentation: Institute on Psychiatric Services 65th Annual Meeting, Philadelphia, PA 2013
6. Levey EJ, Borba CPC, Harris BL, Lekpeh GG, Kekulah I, Oppenheim CE, Thakurathi N, Alhomaizi A, Menyongai JB, DiandyVC, Varnie JN, Julu K, **Henderson DC**. Hopes and dreams of youth in post-conflict Liberia. Poster Presentation at Harvard Psychiatry Research Day, Boston, MA 2013
7. Christian NV, Ameresekere M, Ulloa M, Lange BCL, Kempeh MP, Karnga DG, Fallah M, Payne A, Brown E, Menyongai JB, Harris B, **Henderson DC**, Borba CPC. Liberian traditional healers’ report of open mole and future impacts on cross cultural psychiatry. Poster Presentation at Harvard Psychiatry Research Day, Boston, MA 2014.
8. Eusebio JR, Lange BCL, Ulloa M, Zayas L, Lekpeh G, PayneA, DiandyV, BrownE, Menyongai JB, Harris B, **Henderson DC**, Borba CPC, Vesga Lopez O.Towards assessing psychological distress and symptoms of common mental disorders in post-conflict settings: A qualitative study in Liberia. Poster Presentation at Harvard Psychiatry Research Day, Boston, MA 2014.
9. Lange BCL,Ameresekere M, Ulloa M, Kempeh MP, Karnga DG, Fallah M, Payne A, Brown E, Menyongai JB, Harris B, **Henderson DC**, Borba CPC, Christian NV. Traditional healing practices for depression in Liberia. Poster Presentation at Harvard Psychiatry Research Day, Boston, MA 2014.
10. Lekpeh G, Lange BCL, Ulloa M, Eusebio JR, Zayas L, PayneA, DiandyV, BrownE, Menyongai JB, Harris B, **Henderson DC**, Borba CPC, Vesga Lopez O.Religiosity among war-affected Liberians. Poster Presentation at Harvard Psychiatry Research Day, Boston, MA 2014.
11. Ulloa M, Ameresekere M, Lange BCL, Kempeh MP, Karnga DG, Fallah M, Payne A, Brown E, Menyongai JB, Harris B, **Henderson DC**, Borba CPC, Christian NV. Liberian traditional healers’ interpretations of psychosis and treatment modality. Poster Presentation at Harvard Psychiatry Research Day, Boston, MA 2014.
12. Vesga Lopez O, Lange BCL, Ulloa M, Eusebio JR, Zayas L, Lekpeh G, Payne A, Diandy V, Brown E, Menyongai JB, Harris B, **Henderson DC**, Borba CPC. Understanding the concept of well-being in post-conflict societies: The case of Liberia. Poster Presentation at Harvard Psychiatry Research Day, Boston, MA 2014.
13. Ulloa M, Ameresekere M, Lange BCL, Kempeh MP, Karnga DG, Fallah M, Payne A, Brown E, Menyongai JB, Harris B, **Henderson DC**, Borba CPC, Christian NV. Traditional treatments for substance abuse in Liberia. Poster Presentation at the 2ndAnnual MGH Public and Community Psychiatry Symposium, Boston, MA 2014.
14. Lange BCL, Ameresekere M, Ulloa M, Kempeh MP, Karnga DG, Fallah M, Payne A, Brown E, Menyongai JB, Harris B, **Henderson DC**, Borba CPC, Christian NV. Collaboration amongst traditional healers and western medical practitioners in Liberia. Poster Presentation at the 2nd Annual MGH Public and Community Psychiatry Symposium, Boston, MA 2014.
15. Vesga Lopez O, Ulloa M, Lange BCL, Eusebio JR, Zayas L, Lekpeh G, Harris B, **Henderson DC**, Borba CPC. Assessing psychological status and functioning in individuals exposed to armed conflict: Liberia as an example. Poster Presentation at the XVI World Congress of Psychiatry; Madrid, Spain 2014.
16. Vesga Lopez O, Lange BCL, Ulloa M, Eusebio JR, Zayas L, Lekpeh G, Harris B, **Henderson DC**, Borba CPC. Towards assessing psychological distress and symptoms of common mental disorders in post-conflict settings: a qualitative study in Liberia. Poster Presentation at the XVI World Congress of Psychiatry; Madrid, Spain 2014.
17. Levey EJ, Borba CPC, Harris BL, Opeenheim CE, Thakurathi N, Alhomaizi A, Plasky N, Lange B, Lekpeh GG, Kekulah I, Menyongai JB, DiandyVC, Payne A, Johnson D, Varnie JN, Julu K, **Henderson DC**. Losses and connections: Factors impacting resilience among teens in post-conflict Liberia. Poster Presentation at the 2nd Annual MGH Public and Community Psychiatry Symposium, Boston, MA 2014. Parnarouskis L, Oppenheim CE, Stevenson A, Ulloa M, Schor S,
18. Ameresekere M, Menyongai J, Chukwuezi B, Johnson D, Kouagheu SP, Onyeulo C, Slopadoe SP, Wennah P, Paul G, Morris J, Boykai G, Jackson B, Manyika N, **Henderson DC**, Borba CPC. A Needs Assessment for Health and Mental Health Education and Awareness for Africans in Lowell. Poster session presented at the Massachusetts General Hospital Scientific Advisory Committee Meeting, Boston, MA 2015.
19. Ulloa M, Ameresekere M, Lange BCL, Kempeh MP, Karnga DG, Fallah M, Payne A, Brown E, Menyongai JB, Harris B, **Henderson DC**, Borba CPC, Christian NV. Traditional treatments for substance abuse in Liberia. Poster Presentation at the Massachusetts General Hospital Scientific Advisory Committee, Boston, MA 2015.
20. Ulloa M, Ameresekere M, Lange BCL, Kempeh MP, Karnga DG, Fallah M, Payne A, Brown E, Menyongai JB, Harris B, **Henderson DC**, Borba CPC, Christian NV. Liberian traditional healers’ interpretations of psychosis and treatment modality. Poster Presentation at the Massachusetts General Hospital Scientific Advisory Committee, Boston, MA 2015.
21. Oppenheim CE, Parnarouskis L, Stevenson A, Ulloa M, Schor S, Ameresekere M, Menyongai J, Chukwuezi B, Johnson D, Kouagheu SP, Onyeulo C, Slopadoe SP, Wennah P, Paul G, Morris JB, Boykai G, Jackson B, Manyika N, **Henderson DC**, Borba CPC. Using Community-Based Participatory Research (CBPR) to Conduct a Health and Mental Health Needs Assessment for Africans in Lowell. Poster Presentation at the Massachusetts General Hospital 3rd Annual Public and Community Psychiatry Symposium, Boston, MA 2015.

 |  |